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ABSTRACT 
 
The Bi-directional Relationship Between Gut Microbiota and Autoimmunity 
 
 
by 
 
Trevor O. Kirby 
 
Spring 2018 
 
Humans serve as a major reservoir for a vast number of microbiota.  These microbes have 
evolved symbiotic relationships with humans due to their close proximity with their host.  
As a result, the immune system adapts to the microbiota thus modulating immunological 
function. Autoimmunity is a state in which there are aberrant immune responses 
produced against host tissue.  Intestinal bacteria are directly impacted by instances of 
inflammation brought on by autoimmunity. The complicated nature between 
autoimmunity and bacterial modulation demonstrates a bi-directional relationship.  Here, 
we utilize experimental autoimmune encephalomyelitis, a model for multiple sclerosis, to 
explore the bi-directional relationship that disease and microbiota share.  We demonstrate 
that disease severity, as well as time point post disease induction, shapes the structure and 
function of the gut microbiome.  Additionally, antibiotic intervention modulates the 
symptoms of disease by upregulating the expression of T regulatory cells.   Further, we 
show that a genetically engineered Lactococcus lactis expressing the colonization factor 
antigen I from Escherichia coli acting as an immunomodulatory probiotic reduced the 
severity of disease. 
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Chapter 1: The gut microbiome, multiple sclerosis, their relationship, and therapeutic 
approaches 
Overview 
Bacteria are prokaryotic microorganisms with a vast array of functions and 
characteristics.  Diverse bacterial metabolism allows them to occupy almost every niche 
possible on Earth.  Their range spans everywhere from extreme conditions such as deep 
sea hydrothermal vents to more mild conditions such as on plants growing in temperate 
climates.  As a consequence, every facet of human biology is exposed to bacteria.  
Whether it be from dust in the air to the food consumed, humans are constantly exposed 
to bacteria.  
Generally, there is a misconception that bacteria are harmful to humans and pose 
a threat to human health. There are more bacteria that establish symbiotic relationships 
with us, commensal or mutualistic, than bacteria that are pathogenic.  The symbiotic 
bacteria participate in with their human host are analogous to symbioses present in 
traditional ecological settings.  Commensal bacteria will reside in or on the human host 
and receive nutrients from their host’s diet and or metabolites produced from other 
bacteria.  These bacteria do not help their host but they also do not cause disease for their 
human host.  Mutualistic bacteria will behave much like commensal bacteria but their 
presence will provide a direct benefit to their host.  As science continues to investigate 
the bacteria associated with humans, their apparent function and benefits become more 
apparent. 
 
 2 
 
The Gut Microbiome 
Bacteria must compete and interact with other microbes such as other bacteria, 
viruses, fungi, archaea, and single celled eukaryotes as well as interact with the 
environment around them.  These interactions form intricate microbiomes; a microbiome 
is best defined as the summation of all these microbes as well as the combination of all 
the genetic material from them in a defined space and time. The sum of all microbes 
within a given niche is defined as microbiota. Several types of microbiomes exist and are 
generally defined by the physical space in which they are located.  Although scientists 
study all types of microbiomes, particular interest has been focused on human associated 
microbiomes due to their relevance to human health.  Because of this, and in association 
with its highly complex structure and broad array of effects, the best studied microbiome 
is the human gut microbiome (and by proxy the murine gut microbiome). 
The best studied microbiome is the human gut microbiome (and by proxy the 
murine gut microbiome) that spans the entire digestive tract including the stomach, small 
intestine, caecum, large intestine, and rectum.  Across the geographic location, the gut 
environment varies dramatically in both its physical and chemical nature.  The physical 
and chemical variation dictate the structure of the microbiota present.  For example, the 
approximate pH of the duodenum is 6 whereas the pH of the terminal ileum ranges from 
6-7.4.1  Mucus levels tend to differ between the large and small intestines as well which 
directly regulates the bacterial communities present.2  Although the physical properties of 
the gastrointestinal tract shape bacterial populations, microbes persist and thrive.  
Therefore, the gastrointestinal tract physiology evolved to interact and respond to the 
microbiota present. 
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Bacterial metabolism also plays a role in which taxa are present at differing 
geographic locations.  For instance, fatty acids and simple carbohydrates derived from 
food are absorbed in the small intestines and therefore bacteria that can ferment complex 
carbohydrates are the ones that can survive.3  As a consequence, the Bacteroides are the 
most studied taxa that can perform this metabolic task.4  Additionally, human diet plays a 
critical role at shaping the gut microbiome.  Studies in which humans switch their diets 
from being primarily plant based versus primarily animal based experience a profound 
effect on the composition of the gut microbiota.5  The effect of diet on the composition of 
the gut microbiome generally is centered on the fact that it dictates what nutrients are 
available for the microbiota.  Therefore, nutrient availability as well as retention is 
critical. 
Antimicrobials play an additional role at shaping the structure of the gut 
microbiome.  Specialized epithelial immune cells known as Paneth cells secrete 
antimicrobial compounds that alters the growth of bacteria near the mucosal surface.6  
These compounds are cationic peptides that interacted with charged membranes of 
bacteria.  Some bacteria, however, have evolved to respond to these charged peptides; 
some gram negative bacteria have modifications in the lipid A component of the outer 
membrane which renders them resistant to these peptides.7  Interestingly, however, the 
concentration of antimicrobials are higher towards the proximal end of the small intestine 
which results in higher abundance and diversity in the distal ends.3 
Secreted Immunoglobulin A (sIgA) and other immune system mediated responses 
dictates what bacteria persist where.  Intestinal mucosa contains large quantities of sIgA 
to monitor the gut microbiota.3  The non-pathogenic bacteria becomes coated in sIgA to 
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maintain tolerance from the host.  Coats of sIgA on bacteria reduces inflammatory 
signaling and reduces changes to bacterial gene expression.8  This process allows 
homeostasis between the host and the microbiota to be maintained.  However, this 
process can be sometimes utilized by pathogenic bacteria as well.  In the case of some 
species of Helicobacter, these pathogens are coated in sIgA as well resulting in an 
inappropriate tolerance response by the host.9  Therefore the complexity of homeostasis 
between non-pathogenic bacteria and the host is more complicated than simply just sIgA 
coating.  Some believe that the bacteria themselves have to promote their own tolerance 
to the host for their own survival.  This is shown the case of Bacteroides fragilis.  The 
polysaccharide A component of the bacterial capsule on B. fragilis has been shown to 
exert anti-inflammatory properties by stimulating the secretion of IL-10 by regulatory T 
(Tregs) cells.10  This process is seen in other bacteria as well suggesting that the need for 
self-promoting tolerance is necessary. 
The Anatomy of the Gut Epithelium 
The gastrointestinal tract is the site of interaction between the body’s largest 
concentration of immune cells and the gut microbiota.11  The gut epithelium acts as a 
major barrier between the external environment and the host’s internal environment.  The 
human digestive tract essentially is a long tube; starting from the mouth and extending 
down the esophagus, past the stomach and through the small intestines and large 
intestine, finally ending past the colon at the anus; everything humans eat needs to be 
separated from the inside of the body. 
 Goblet cells in the intestinal epithelium produces mucus to form a matrix between 
the external environment and the intestinal epithelial surface.12  Besides the mucus layer, 
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only a single layer of epithelia separates the intestinal lumen contents from the 
underlying connective tissue and interior milieu.13  Due to this, the intestinal epithelium 
developed specialized cells types to deal with the exposure.  As previously discussed, 
Paneth cells play a critical role in maintaining the security of the gut epithelium by 
secreting antimicrobial peptides.  Additionally, cells expressing CD24 resides in the 
colonic crypts which elicit similar responses to the Paneth cells.14 
 The thin layer of epithelium generates a barrier that can prevent material from the 
intestinal lumen from entering the interstitial space of the body.  Tight junction protein 
complexes regulate the paracellular permeability of the intestinal epithelium.13  The 
permeability of the epithelium varies across the intestines geography and is largely 
determined by the amount of tight junction protein complex expression.  The protein 
complex consists of transmembrane proteins such as occludin, claudin, junctional 
adhesion molecules, tricellulin, and intracellular scaffold proteins like zonula 
occludens.13  The pathogenesis of several diseases such as inflammatory bowel disease, 
celiac disease, and even food allergies have been attributed to the hyperpermeability of 
the intestinal barrier.15  Interestingly, alterations in normal gut microbiota has been noted 
to cause changes in intestinal permeability.16  In the case of Gulf War Illness, chemical 
injury results in the alteration in intestinal microbiota resulted in a down regulation of 
occludin expression and an increase in intestinal permeability.  The leachates then cause 
endotoxemia leading to the upregulation of toll like receptor-4 activation in the intestine 
as well as the brain.16 
Because of the high intake of microbes via digestion and the critical role intestinal 
epithelia plays, the immune system and intestinal physiology evolved to monitor the 
 6 
 
traffic.  The lymphatic system is a network of vasculature that allows leukocytes to travel 
the body and monitor antigens. For the gut, there is a specialized set of lymphatic tissue 
known as the gut associated lymphoid tissue (GALT).  The GALT is comprised of the 
Peyer’s patches, mesenteric lymph nodes, lymphatic vasculature, as well as other 
lymphoid aggregates.  These structures work in tandem to protect the gut from 
pathogenic microbes while monitoring the commensal or mutualistic bacteria. 
The Gut/Immune System Nexus  
As bacteria and their metabolites persist in the gut, the GALT-associated immune 
cells must monitor every aspect of the intestinal lumen to catch and eliminate pathogens.  
M cells, a specialized epithelial cell of mucosa-associated lymphoid tissue, transports 
antigens from the intestinal lumen to immune cell populations.  M cells allow dendritic 
cells to sample antigens from the lumen and endogenously prepare the antigen for 
presentation to T effector cells via the major histocompatibility complex (MHC) class II 
molecule.  This process then, in turn, can activate the T cells and differentiate them into 
specialized effectors to perform functions necessary for dealing with the microbe 
expressing the activating antigen.  Whether it is to mount an immunological response or 
to disregard the antigen, the interaction between the host immune system and the microbe 
will occur.  This process is mediated by the subsets of T cells as well as anergy.  
In the case of pathogenic antigens, the need to activate pro-inflammatory T cells 
may be necessary.  T helper (Th) cells such as Th1, Th2, and Th17 can help mobilize and 
recruit innate immune cells to the site of the pathogen.  This process is mediated by the 
secretion of cytokines and chemokines.  Cytokines are molecules such as interferons, 
interleukins, growth factors, and other compounds that have some effect on other immune 
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cells.  CD4 T cells express surface receptors known as T cell receptors that can identify 
antigens presented by MHC molecules.  Upon this union, the naïve T cell will 
differentiate into one of the various T helper cell subsets depending on the additional 
signaling molecules the naïve T cell encounters during co-stimulation.  As an example, 
Th1 cells can be activated after co-stimulation and go on to secrete interferon-gamma 
(IFN-γ) to activate other Th1 cells in the immediate area.17  The non-cognate stimulation 
of Th1 cells allows the immune system to clear pathogenic intracellular bacteria.  These 
cytokines and chemokines recruit innate immune cells such as neutrophils to the site of 
the infection; the immune system then can eliminate the threat of the pathogen via 
phagocytosis, neutralizing antibodies, or antibody mediated engulfment. 
In the case of non-pathogenic antigens, there is a need to activate anti-
inflammatory T cells to prevent immune cell mediated clearance of the pathogen.  As 
previously stated, not all of bacteria are pathogenic but rather commensal or mutualistic.  
Therefore it is critical for the immune system to have a way to virtually ignore the 
antigens of these non-harmful bacteria. Previously discussed, B. fragilis had the ability to 
stimulate its own immunotolerance by stimulating the production of Tregs which would 
secrete IL-10.10   
Additionally, anergy could also be used to prevent an immunological response 
against non-pathogenic bacteria.  Anergy is defined as being the absence of a normal 
immunological response to an antigen; achieving anergy against non-pathogens could be 
another way to ignore non-pathogenic antigens.  Toll like receptor-7 can be engaged 
resulting in an intracellular calcium flux with the activation of a NFATc2-dependent 
anergic gene expression program that ultimately results in T cell non-responsiveness.18  
 8 
 
The processes that maintain the balance between pro- and anti-inflammatory 
processes are complicated and in some cases depend on the bacteria or viruses 
present.10,18  Additionally, the gut microbiome is shaped by various factors including host 
genetics, geographical location, diet, lifestyle choices, prescribed pharmaceuticals, mode 
of delivery during birth, antibiotic exposure, and possibly even disease states themselves.  
When these factors tip the gut microbiome out of balance, there can be an induced 
imbalance between these pro- and anti-inflammatory responses that can result in disease.  
This proposed disease model is known as dysbiosis: gut microbial imbalances that result 
in, or are a result of, disease states.  Generally, labs are investigating whether these 
alterations in gut microbiota result in disease.  However, it is possible that alterations in 
the balance between pro- and anti-inflammation can alter the structure and function of the 
gut microbiota as a function of diseased states. 
Multiple Sclerosis and Autoimmunity 
Autoimmunity is best described as being a process in which the host’s immune 
system fails to distinguish self from non-self and begins to elicit immunological 
responses against host tissue.  Mechanisms that drive autoimmunity remain to be 
elucidated; however, it generally is understood that exacerbated pro-inflammatory 
responses can exacerbate the tissue damage that characterizes the process of 
autoimmunity.  Therefore, understanding the extent of inflammation induced by dysbiosis 
becomes critical to investigate.  The importance of gut microbiota in context to immune 
function can be seen when comparing traditional mice to gnotobiotc mice. Gnotobiotic 
mice exhibit reduced immune function with physiological abnormalities such as 
increased intestinal permeability.  Dysbiosis can be induced by the same environmental 
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factors that have been described to potentially illicit autoimmunity.  Moreover, dysbiosis 
has been noted in several experimental models of autoimmunity as well as patients 
suffering from autoimmunity.19-22  These phenomena can provide evidence that intestinal 
dysbiosis is critical in the development of autoimmune disorders. 
Our lab primarily focuses on Multiple Sclerosis (MS), a clinically common 
autoimmune disease.  MS affects millions of individuals worldwide; many of these 
individuals reside in northern geographic locations such as the Pacific Northwest.  For 
these individuals the quality of life slowly diminishes as the disease progresses, as the 
host immune system attacks the insulating structure known as the myelin sheath that 
surrounds the axon shaft of neurons in the spinal cord.23  When the sheath is degraded, 
the ability for electrical signals to be sent through the axon is reduced thus resulting in 
paralysis and other symptoms. The most prevalent form of MS is relapsing-remitting MS 
(RRMS) that affects 85% of the total patient population; RRMS is initially diagnosed as a 
syndrome of neuronal dysfunction with a repeating series of relapses and remissions that 
follow over time.24  Approximately 70% of RRMS patients develop secondary-
progressive MS (SPMS), which causes a steady and progressive neurological 
impairment.24,25  The precise reason as to why immune cells destroy myelin remains 
unclear.24,25  In MS, the myelin sheath that surrounds the axons of neuronal cells is 
degraded by host immune cell populations.  Although the exact etiology is debated, there 
are hallmark events that undeniably occur. 
Generally, MS arises in genetically susceptible individuals.  Genetic variation is 
attributed to about one third of the disease risk.26  Environmental conditions as well as 
lifestyle choices play an additional factor in disease risk. Lacking a predominant 
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exogenous risk factor, there is ambiguity as to whether MS starts in the periphery or in 
the central nervous system (CNS).27  In peripheral models of MS, pathogenic T cells are 
activated and subsequently released to the draining lymph nodes.27  From the draining 
lymph nodes, these pathogenic T cells can enter circulation and gain access to the central 
nervous system by trafficking with activated B cells and monocytes.27  Intrinsic models 
propose that the rise of autoreactive lymphocytes is secondary to intrinsic CNS damage.27  
Additionally, autoreactive B cells can be found in the meninges, parenchyma, and 
cerebrospinal fluid.27  These autoreactive B cells can secrete antibodies which tend to 
increase with age in MS patients.28  There is a lack of known autoantigens which makes 
the mechanisms behind autoreactive B cell pathology speculative;27 however, next-
generation sequencing has provided evidence that antigen-experienced B cells potentially 
go through maturation prior to entering the CNS.29  Inflammation is a primary result from 
autoreactive lymphocytes.  These responses cause axonal damage and could potentially 
trigger a self-sustaining chronic neurodegenerative process.27  As a result, resident CNS 
cells such as the microglia and astrocytes additionally secrete inflammatory molecules 
further exacerbating the neurodegeneration.30  The extent to which all these cell 
populations work in tandem to cause disease highlights the need to prevent the initial 
onset of inflammation and neurodegeneration. 
Compounding the magnitude of autoreactive immune cell populations, defective 
Treg cells have also been noted in MS.31  Defective Tregs could contribute to the 
production of autoreactive lymphocytes and additionally exacerbate the effects of 
preexisting autoreactive lymphocytes.  Studies show that Tregs are lower in numbers and 
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have reduced functionality in patients with MS.32  Ultimately, it is the occurrence of 
defective Treg cells that can help explain why autoreactive immune cells arise. 
The degradation of the myelin sheath by host immune cells is generally mediated 
by the T helper 17 (Th17) cells.33  The imbalance between effector T cell and Tregs leads 
to pro-inflammatory states which characterizes MS.  The increased levels of Th17 cells 
secrete pro-inflammatory cytokines and chemokines that recruit immune cells for the 
degradation events.  Reduced and dysfunctional Tregs will fail to keep the exacerbated 
Th17 in check resulting in myelin degradation.  
  Gut microbial imbalances tend to shift towards a pro-inflammatory state that 
have profound effects on the intestinal physiology of the individual.  Additionally, 
dysbiosis has been associated with intestinal barrier disruptions.  When the integrity of 
these tight junction protein complexes diminishes there is an increase in intestinal 
permeability; the bacterial antigens can pass out of the intestinal lumen and travel to other 
locations in the body.  As a result, levels of antigens, like the endotoxin 
lipopolysaccharide, can increase in the blood circulation which could have systemic 
inflammatory effects.34 Systemic translocation of bacterial antigens can have a profound 
effect on CNS immunity and impact the integrity of the blood-brain barrier.35 This 
process can result in the ultimate passage of autoreactive lymphocytes into the CNS and 
have direct access to the myelin sheath. 
The Bi-directionality of the Gut Microbiome 
 As previously discussed, autoimmunity has been shown to be impacted by the gut 
microbiome.  However, it has also been theorized that disease itself can shape the 
 12 
 
structure and function of the gut microbiome. What this implies is that there is a bi-
directional relationship between diseased states and the structure and function of the gut 
microbiome.  This then raises more questions; what comes first: the disease or the 
aberrant gut microbiome? 
 In instances of some autoimmunity, the aberrant gut microbiome precedes the 
onset of disease.  This phenomenon can be seen directly with Type 1 Diabetes (T1D).  
Intestinal dysbiosis has been noted in both humans and animal models of T1D.  In a study 
conducted by Costa et al., the murine model for T1D was protected against the 
development of insulitis when treated with antibiotics.36  The model utilized in this study 
was a streptozotocin-induced T1D models in which the onset of insulitis is brought on 
upon by the bacterial translocation event.  The utilization of antibiotics prevented 
bacterial translocation and thus prevented the onset of disease.  Moreover in humans, 
bacterial translocation has been theorized as being a major factor that leads to insulitis.  
Bacterial translocation through the duodenum as a result of intestinal dysbiosis can cause 
the bacterial antigens in the pancreatic ducts to recruit immune cell populations resulting 
in the destruction of β-cells.  
 On the other hand, there is an increasing interest in determining how disease itself 
shapes the gut microbiome.  Risk factors that have been associated with autoimmunity 
also impact the gut microbiome.37  Additionally, autoimmunity can directly impact how 
the immune system responds to the gut microbiota.  In the case of inflammatory bowel 
diseases, the immune system targets resident microbiota thus altering the overall structure 
of the gut microbiome.38  Targeting non-pathobionts and clearing them from the 
intestines could have profound impacts on the immune system of the host.  If a 
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populations of bacteria that promotes anti-inflammatory responses are eliminated it is 
possible that unchecked systemic inflammation could occur thus further exacerbating the 
initial autoimmune disease. 
 In the case of MS, dysbiosis is present.39-41  Therefore, there is ample data to 
support the hypothesis that the gut microbiome can play a role in the development of MS.  
However, very little is known about how MS affects the composition of the gut 
microbiome.  Understanding how MS pathology affects gut microbiota can give insight 
to novel therapeutic approaches to impact disease progression.  Similarly, dysbiosis 
drives disease progression in the inflammatory bowel disease model, therefore it is 
possible that dysbiosis also promotes inflammation in the MS model.  It is hypothesized 
that there is a bi-directional relationship between the gut microbiota and MS.  The 
structure and function of the gut microbiome shapes MS pathology at the same time MS 
disease progression also shapes the structure and function of the gut microbiome. 
 The structure of the dysbiotic MS gut is so influential to disease progression that 
fecal transplantation of the gut microbiome can influence the progression of experimental 
autoimmune encephalomyelitis (EAE), a model for MS in mice.  When fecal material 
from discordant monozygotic twins was transplanted into mice, there was a profound 
impact on spontaneous EAE disease incidence.42  The MS gut microbiome had the ability 
to increase the likelihood of spontaneous EAE induction in mice as opposed to the 
healthy twin.  Moreover, the stool from MS patients also increased the severity of EAE in 
mice.43  Therefore, it is clear that targeting the gut microbiome might have profound 
impacts on MS pathology. 
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Targeting the Gut Microbiome with Therapeutic Options 
 As summarized earlier, recent experimental evidence and clinical data suggest 
that the gut microbiome might be a major factor regulating autoimmunity.  Targeting the 
gut microbiome with therapeutics could have profound effects in disease progression as 
well as managing symptoms of disease.  The extent and approach towards modulating the 
gut microbiome can follow many directions; it is crucial to balance the positive and 
negative impacts of each therapeutic option.  Gut microbiome-based therapeutic 
approaches could have beneficial effects in terms of disease management but also have 
unintended adverse side effects.  Furthermore, some therapeutic options can work for 
some autoimmune diseases but not others.  Therefore, again, assessing proposed 
therapeutics are crucial and developing therapeutics with less negative consequences is 
essential. 
Antibiotic Therapy 
Utilizing antibiotics to therapeutically target the gut microbiome has been 
proposed for models of Type 1 Diabetes as well as Fulminant Ulcerative Colitis.44,45 
Additionally, a study conducted by Nakamura et al. set out to test the efficacy of an 
antibiotic cocktail on an experimental autoimmune uveitis (EAU) model. Autoimmune 
uveitis has both a genetic and environmental culmination that impacts disease 
susceptibility, and is characterized by a distinct increase in Th17 cell populations with a 
decrease in Tregs cell populations.46  Utilizing an antibiotic cocktail consisting of 
ampicillin, vancomycin, neomycin, and metronidazole, the researchers noted that clinical 
scores of EAU were significantly reduced compared to the control group when the 
antibiotics were administered orally.  The bacterial phyla Firmicutes and Bacteroidetes as 
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well as the class of Alphaproteobacteria were reduced while there was an increase in the 
class of Gammaproteobacteria.  More importantly, the utilization of antibiotics 
significantly increased the expression of CD4+Foxp3+ Treg cell populations with a 
reduction in IL-17 producing Th17 cells.46  Although the reduction in Th17 cells was not 
significantly reduced, it was still reduced substantially.  Taking this all into consideration, 
the treatment of broad spectrum antibiotics conferred protection against the EAU 
pathology. 
Experimental Autoimmune Encephalomyelitis (EAE), a model disease for MS, 
has also been explored in the context of antibiotic intervention.  A study by Ochoa-
Repáraz et al. demonstrated that broad-spectrum antibiotic interventions affected the 
balance between inflammation and inflammatory regulation in EAE by modulating 
intestinal microbiota and, as a consequence, Treg cell populations.47  Additionally, 
Yokote et al. reported similar findings but noted that the alterations in intestinal 
microbiota impacted the Natural Killer T cell populations.48  These experiments analyzed 
the impacts antibiotic intervention could have on modulating EAE in SJL as well as C57 
mice.  In the case of germ-free mice, mice with no microbiota, it was noted that 
colonization with segmented filamentous bacteria induced intestinal Th17 cell 
production.49  Additionally, the colonization of segmented filamentous bacteria was 
correlated with the increased expression of inflammatory genes.49  In the case of EAE, 
when germ-free mice were monocolonized with segmented filamentous bacteria they 
experienced exacerbated symptoms of EAE which generally are not present in the germ-
free model of EAE.50 
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 CNS diseases also have studied in terms of how antibiotics impact disease 
pathology.  Parkinson’s disease (PD) patients report gastrointestinal distress as well as 
exhibit intestinal inflammation well before symptoms of motor deficits.51-53  A study 
conducted by Sampson et al. hypothesized that alterations in the gut microbiota by 
antibiotic interventions could alleviate PD pathology due to the association of intestinal 
complications and the tight interactions between the gut and the CNS.54  The treatment of 
broad-spectrum antibiotics did, in fact, confer protection against motor dysfunction in a 
murine model.  These findings support the notion that therapeutic targeting of the gut 
microbiome with antibiotics may be efficacious. 
 In the cases above, antibiotic interventions have conferred protection in these 
models of disease by altering the gut microbiome.  However, the usage of broad spectrum 
antibiotics can also have adverse effects by the same mechanism.  Clostridium difficile, 
an opportunistic pathogen, can infect the host after antibiotic treatments with symptoms 
ranging from diarrhea to pseudomembranous colitis and can be in some cases life 
threatening.55  The exposure to antibiotics cause structural changes in the gut microbiome 
leaving the host susceptible to opportunistic infection from C. difficile as well as other 
enteric pathogens.56  Children exposed to antibiotics within the first three years of life 
exhibit lower diversity in their gut microbiome.  Moreover, these microbiome structures 
are less stable in exposed children than in non-exposed children.57 
Phage Therapy  
In response to the negative impacts of broad spectrum antibiotic usage the notion 
of using bacteriophage (phage) as a therapeutic has been discussed.  Phage are bacteria-
specific viruses that can be altered to target bacterial populations of interest while leaving 
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others untouched.  The oral delivery of phage has been considered to be safe and have the 
capability to bypass intestinal epithelia and penetrate the GALT as well as the blood 
stream.58,59  This ability to penetrate the GALT as well as the blood stream makes phage 
therapy extremely attractive to deal with bacterial translocation that can lead to diseased 
states such as those seen in T1D. 
Phage play a critical role in shaping the gut microbiome naturally and constitutes 
the bulk of the intestinal viriome.60,61  However, phage can also be pathogenic by 
contributing to intestinal dysbiosis; their uncontrolled destruction of beneficial bacteria 
can have consequences to the overall structure and function of the gut microbiome.62  
Additionally, phage also can have the unintended impact of horizontally transferring 
antibiotic resistance to their bacterial hosts.63  Lysogenic phage have had antibiotic 
resistance genes associated within their genomes.64  To some, this has rendered the notion 
of phage therapy obsolete.  However, researchers have been designing “smart” phage 
cocktails that bypass horizontal gene and appear promising.65  Ultimately, there is still a 
lot of unanswered questions and concerns in regards to the safety and efficacy of phage 
therapies in terms of unintentional microbiome impacts. 
Fecal Transplantation 
 The approach of antibiotic interventions and phage therapeutics is to target 
bacterial populations and remove or reduce them from the gut microbiome.  Fecal 
transplantations act as whole gut microbiome replacements in hopes of correcting 
aberrant gut microbiome structures and functions.  The efficacy of fecal transplantations 
is also quite high; thus, fecal transplantations is a common therapeutic to treat patients 
with C. difficile.66,67  Conceptually, by eliminating the host’s aberrant gut microbiome 
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and replacing it with a healthy gut microbiome, the diseased state will be rectified.  This 
largely is the case in patients suffering from C. difficile infections and has revealed 
infection clearance with a single treatment.66,67  The efficacy of fecal transplantations has 
promise in other diseases, including autoimmunity and neurological disorders, as well.  
 In the instance of autoimmunity, again, fecal transplantations has been proposed 
as a therapeutic strategy to treat irritable bowel syndrome as well as inflammatory bowel 
disease.68  In inflammatory bowel disease, there is instances of dysbiosis with an increase 
in pro-inflammatory bacterial species.69  A meta-analysis from Colman et al. showed that 
fecal transplantation therapy put 45% of patients into clinical remission and reduced the 
need for other forms of anti-inflammatory therapeutics.70  Symptom rescue was attributed 
to microbiota manipulation; the gut microbiome changes in the patients in response to 
fecal transplant therapy.71 
 Satisfactory results from fecal transplantation are apparent, however there are still 
concerns regarding safety.  For example, some of these concerns regard the route of 
administration, frequency of applications, screening the microbiota from the donor, the 
preparation protocol of the stool sample from the donor, what antibiotics should be 
administered and their frequency prior to fecal transplantation, among others.69  Some of 
these concerns are very valid and have been partially explored.  For example, in the study 
by Friedman-Korn et al., instances of aspiration occurred in two patients when the fecal 
transplantation was administered via gastroscopy.67  It was proposed that that 
colonoscopy would be a safer route for the therapy.  This claim was then assessed later in 
the study by Bamba et al.66  Still, several concerns remain.  The impact donor stool can 
have an immense effect on an individual.  Data supports the notion that fecal 
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transplantations can play a role in the development of obesity.72  Ultimately, the risks and 
rewards of fecal transplantation therapy still needs extensive exploration. 
Dietary Supplementation 
 Diet, itself, plays a major role in shaping the structure of the gut microbiome.  By 
manipulating compounds and nutrients the gut is exposed to, it is possible to alter the 
structure and function of the gut microbiome.  Western diets generally consist of high 
amounts of saturated fats and carbohydrates which can lead to chronic inflammatory 
states.73  Recognizing the impacts of the Western diet and identifying routes to 
supplement the diet to reduce the negative impacts and chronic inflammatory states could 
be a therapeutic avenue to assess. 
 Naturally occurring compounds have been noted to have profound impacts on 
metabolic health.  Chlorogenic acid is a phenolic acid commonly found in beverages 
commonly ingested by humans worldwide, such as coffee and tea.74  It has been shown to 
inhibit glucose-6-phosphate translocase as well as hepatic glucose-6-phosphatase.75  
These properties would limit the amount of carbohydrate absorption by the small 
intestine as well as the extent in which glucose is released.75  Chlorogenic acid has also 
been noted to have antimicrobial activities against some bacterial species that constitute 
parts of the gut microbiome.76  Glycyrrhizin, a compound found in the roots of the 
Glycyrrhiza glabra plant, has also been identified for its anti-inflammatory properties.77  
When glycyrrhizin was administered into high-fat induced obese rats, the glycyrrhizin 
caused the rat to have reduced insulin resistance, lose weight from the diet, and reduced 
obesity-induced oxidative stress.78  The impact glycyrrhizin has on bacteria has not been 
noted nor has it been explored in context to the gut microbiome.  The overall impacts 
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these plant based compounds have on the gut microbiome is vastly unknown and 
warrants further investigation. 
 Utilizing dietary supplements as a therapeutic avenue for MS is still largely 
unexplored.  The usage of probiotics however, has been gaining attention.  A probiotic is 
generally described as bacteria that is administered orally to have some beneficial impact 
on the health of the individual.  Moreover, probiotics are a non-toxic immunomodulatory 
agent that can orally be used in conjunction with current therapeutics for MS.79 Studies 
have shown that oral administration of probiotics have positive immunomodulatory 
effects that could work in tandem with current pharmaceutical therapeutics.  Probiotics 
will further be discussed later. 
Limitations of Current Therapeutics 
 Ultimately, all these therapeutic options have not been explored fully been for 
MS.  Moreover, the therapeutics available for MS are quite limited.  There is no cure for 
MS and most of the therapeutics available only treat symptoms of the disease.  Current 
pharmaceuticals exist that act as immunosuppressive or immunomodulatory agents; 
however, many of them have limited efficacy and have in some cases severe side 
effects.80  Moreover, there is yet no commercial therapeutic for secondary progressive 
MS.  Because of the current limits of the pharmaceuticals for MS, there is a need to 
explore novel therapeutic avenues. 
Testing a potential therapeutic option for MS 
 The effect of the gut microbiome on MS pathology is a promising avenue of 
investigation.  Therefore, characterizing the microbial profile of the MS gut as compared 
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to healthy gut microbiomes, as well as other autoimmune diseases, could be insightful.  
By investigating the structure of these microbiomes it is possible to understand what 
microbes are contributing to the pro-inflammatory state and lack of anti-inflammation.  
From this data, it is possible to then develop probiotic mixtures containing critical 
bacterial populations, which can increase Treg numbers, but are diminished in the MS gut 
microbiome. 
 Here, we propose to explore the bi-directionality between the etiology and 
pathology of MS and the gut microbiome of the host.  To achieve this goal, we will 
analyze the structure and function of the gut microbiome when CNS inflammatory 
demyelination is induced in EAE mice, and in healthy control mice.  From there, we will 
confirm the role the gut microbiome plays on symptoms of MS by subjecting EAE mice 
to broad-spectrum antibiotics and assessing the clinical scores of these mice during 
disease progression (as previously done in other models of EAE).47,48  From the data 
obtained from the structural analysis of the EAE gut microbiome, we will test the 
efficacy of a probiotic on the symptoms of EAE in mice. 
 We hypothesize that the gut microbiome of EAE differs between individuals 
based on the severity of disease as well as the time point after disease induction.  The 
broad-spectrum antibiotic cocktail will reduce disease severity when mice are 
subjected to the antibiotics during the early, more pro-inflammatory phase of EAE 
as opposed to later stages of disease.  Moreover, we also propose that the oral 
treatment of EAE mice with a genetically-engineered probiotic strain of Lactococcus 
lactis designed to promote anti-inflammatory responses will confer protection in the 
severity of EAE. 
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Chapter 2: Analyzing the Effect of CNS inflammatory demyelination on the 
Composition of the Gut Microbiome using a murine model of Multiple Sclerosis  
Introduction 
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system 
(CNS) MS in which the host’s immune cells degrade the myelin sheath of neurons.  This 
degradation is brought on by a breakdown in self-tolerance which allows the production, 
mobility, and function of these auto-destructive immune cells.1  The exact mechanism of 
why this phenomenon occurs is yet to be defined.  However, it is believed that this could 
be a result of a deficit in T regulatory cell (Treg) populations.1  Moreover, when therapies 
targeting enhancement of defective Treg populations are applied in the murine model of 
experimental autoimmune encephalomyelitis (EAE), symptoms of disease progression 
are ameliorated.1  Seeing that the dysfunctional Tregs may play a critical role in MS 
pathology, it is critical to explore what is causing the defect in Tregs.  
Recently, researchers have begun to make the association between the defunct 
Treg populations in MS and the changes in the gut microbiome.  A recent study by 
Cekanaviciute et al. showed that certain microbial taxa were diminished in MS patients 
as compared to healthy individuals.2  More so, some of these reduced taxa are associated 
with the expression of IL-10+FoxP3+ Tregs.2  Moreover, the gut microbiome of MS 
patients can exacerbate the severity of EAE in murine models.2  For instance, MS 
patient’s stool can cause spontaneous autoimmune encephalomyelitis in murine models.3  
These results show the clear connection between the gut microbiome and its role in the 
etiology of MS.  Further understanding the potential mechanisms of this relationship is 
required. 
 35 
 
The gut microbiome has been attributed several inflammatory conditions as well 
as CNS disorders including MS.2-6  An investigation by Ochoa-Repáraz et al. showed that 
the gut microbiome plays a role in disease pathology in the EAE model as well.7  
Moreover, the gut microbiota regulates the function of regulatory immune cells and could 
provide protection from EAE.7  Therefore, understanding the composition of the gut 
microbiome in the EAE model could provide insight into avenues for novel therapeutics.  
It is important first to characterize the gut microbiome at various points in EAE 
progression as well as to compare the differences between gut microbiome compositions 
in differing severities of disease. 
The non-obese diabetic (NOD) mouse model of EAE is characterized by an early 
stage of low grade disease severity followed by a more prolonged and exacerbated phase.  
By being a longer more drawn out model of disease, it allowed us to analyze the gut 
microbiome in a controlled fashion; it permitted for the composition of the gut 
microbiome at various time points of the disease as well as the severity of the disease to 
be analyzed.  This makes the NOD model a more attractive model organism as opposed 
to C57 or SJL strains.  Further, in EAE studies, mice that suffer from milder forms of 
disease are not evaluated exclusively; we aim to show structural and functional 
differences between the mild form of EAE, the severe form of EAE, and mice no 
subjected to EAE. 
In this study, we hypothesize that the gut microbiome composition will differ 
between the various stages of EAE progression in a murine model of disease already 
established in the NOD mouse.8-10  Further, we also hypothesize that the gut microbiota 
will differ depending on the severity of the disease.  These alterations in gut microbiota 
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will lead to altered metagenomic functions and potentially explain differing severities of 
EAE.  Our experimental aim is to provide evidence that the gut microbiota differs as a 
function of disease status. 
Materials and Methods 
Mice and Treatments 
Ten-week old female NOD ShiLt (NOD/ShiLt) mice obtained from the Jackson 
Laboratories were utilized for the experiment.  All aspects of animal use and care were 
conducted in accordance with the institutional policies for animal health and well-being 
under Eastern Washington University. 
EAE induction 
EAE was induced using Hooke KitTM for EAE induction (Hooke Laboratories, 
EK-2110) containing 200 µg MOG35-55 emulsified in 200 µl of complete Freund’s 
adjuvant (CFA).  Each mouse was initially challenged with a single subcutaneous 
challenge.  On days 0 and 1 post-challenge, each mouse received 400 ng of Bordetella 
pertussis toxin intraperitoneally (List Biological Laboratories, Campbell, CA; provided 
with the Hooke KitTM for EAE induction).  Mice were monitored and the disease 
progression was scored daily by blinded observers as previously described: 0, clinically 
normal; 0.5, limp tip of the tail (when picked up by the base of the tail, the tail still has 
tension except for the tip); 1, limp tail (no tail tension observed); 1.5, limp tail and 
inhibition of the hind legs with a slight wobble when the individual walks; 2, limp tail 
and hind leg weakness, the wobble in each step is more pronounced, mouse exhibits poor 
balance;2.5, limp tail, and the hind legs drag; mouse exhibits poor balance; 3, limp tail, 
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hind legs exhibit complete paralysis, or limp tail with one front leg and one hind leg 
exhibiting complete paralysis; 3.5, limp tail, hind legs exhibit complete paralysis, and 
mouse can move, but if placed on its side it cannot right itself back up; 4, limp tail, hind 
legs exhibit complete paralysis, the front legs are starting to show signs of paralysis, and 
the mouse is moving minimally but still appears to be alert and eating; 5, limp tail, hind 
legs exhibit complete paralysis, mouse exhibits minimal movement in front legs, and the 
mouse expresses minimal or no reaction to contact.11  In accordance to IACUC policies, 
mice exhibiting a score of 3.5 or higher were sacrificed with primary chemical euthanasia 
via carbon dioxide asphyxiation followed by secondary physical euthanasia via cervical 
dislocation.  The first two days of concurrent scores of 0.5 or higher were considered and 
documented as the onset of disease per individual.  Type 1 diabetes will spontaneously 
develop in NOD mice at week 14-20 of age unless CFA is administered.12-14  For 
breeding purposes, we administered CFA to the breeding pairs to prevent the onset of 
insulitis.  Diabetic mice were not treated with CFA or MOG35-55. 
Fecal pellet isolation and 16S rRNA sequencing 
Aseptically, fecal pellets were collected on days 0, 14, 30, and 58 and were stored 
at -80 oC.  Samples were sent to AKESOgen (Norcross, GA) for 16S rRNA analysis of 
the gut microbiome.  Qiagen DNA stool extraction kits were used to isolate DNA.  1 
ng/ml of DNA aliquots were analyzed using PCR with primers specific to the variable 
region 4 (V4) of the prokaryotic 16S rRNA gene.  Library preparation and sequencing for 
V4 amplicon sequencing was performed on the Illumina MiSeq V2 (2 x 250bp) 
chemistry.  AKESOgen used a protocol that combined the 2-steps in 1-step of 
amplification with forward primer (515F) and indexed reverse primer (806R).  Once the 
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sequencing was performed, we used a cloud-based web application that facilitates the 
analysis of microbiome data from the Office of Cyber Infrastructure and Computational 
Biology (OCICB), National Institute of Allergy and Infectious Disease (NIAID). 
Utilizing Nephele from the Nation Institute of Health (NIH) 
(http://nephele.niaid.nih.gov/) in 2016 the data was analyzed using QIIME and R was 
used for the statistical analysis. 
 A total of 60 samples were compared using the QIIME FASTQ paired end 
protocol. Samples were pre-processed with a Phred quality score with a mean of 19 and  
a 99% base pair accuracy was observed.  Quality filters were applied to obtain a median 
sequence length of 253.0 per sample. 23435 total observations were found. The 
maximum and minimum number of counts obtained per sample were 573,715.0 and 
174,345.0 respectively, with a mean of 287,059.183 +/- 75,305.628 (+/- the standard 
deviation).  Reads that were demultiplexed were clustered into OTUs open reference 
approach by comparison with the Greengenes database allowing sequences clustered at 
97% similarity.  Analysis included the identification of chimeras with 6,119 chimeras 
found and removed using UCHIME.  The OTU table was rarified to 174,344 sequences 
per sample.  From the OTU table, the data was normalized for chromosomal redundancy 
in QIIME and chromosomal data was collected from the Greengenes database per OTU 
read.  This generalized data was then assigned putative metagenomics functions based on 
each OTU read.  This data was set aside from the OTU table for further statistical 
analysis in R. 
 The abundance of each taxa was analyzed using the phyloseq package in R.15  We 
visualized the compositional heterogeneity of the microbial community of each sample at 
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every time point of collection and at each taxonomical level using non-metric 
multidimensional scaling (NMDS),16 the ordinate function in the phyloseq package and 
the metaMDS function in the vegan package, and the Bray-Curtis dissimilarity Index.  
We used 6 dimensions as it produced the lowest amount of stress, defined as the 
difference between the original dissimilarity and the dissimilarity based on a simplified 
combination of the original taxa. 
 Public access to raw sequences can be found at Sequence Read Archive (SRA) at 
NCBI (BioProject ID: PRJNA383155). 
Statistical Analysis 
Area under the curve analysis followed by one-way ANOVA and multiple 
comparisons tests were applied to show differences in EAE scores of no EAE, mild EAE, 
and severe EAE mice.  Weights were compared by two-way ANOVA followed by 
multiple comparisons test.  To compare severity index as well as the onset of disease, 
Mann-Whitney tests were used.  p-values < 0.05, <0.01, <0.001, and <0.0001 were 
indicated.  The effect of disease on the overall microbiota structure was visualized by 
plotting the results by NMDS in 2 dimensions.  Plots were obtained using the R vegan 
package.  After multiple iterations, the one showing the lowest stress was used to 
generate visuals and for statistical permutational Multivariate Analysis of Variance Using 
Distance Matrices, ADONIS,18 a permutational form of multivariate analysis of variance 
(MANOVA).  Since it is a permutational method, it produces slightly different p-values 
each time.  To obtain reliable p-values, we repeated the ADONIS method 10,000 times 
and reported the average of those p-values for each taxonomical level, each time-point, 
and each comparison (Table 2.2).  Genus-level counts were compared using the non-
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parametric Wilcoxon Rank-Sum test (when comparing 2 sample or matched samples) 
(Fig. 2.4) Differences were considered significant with a p-value < 0.05.  Putative 
metagenomic functions assigned to the intestinal microbiota at each time point of fecal 
collection was analyzed by two-way ANOVA followed by multiple comparisons test 
(Table 2.3). 
Results 
 We induced active EAE in 10 week-old female NOD mice as described 
previously.8-10  EAE in NOD mice shows an incidence rate of disease of approximately 
75%.  In our study 31 out of the total 45 mice experimentally induced with EAE (68.9%) 
showed symptoms of disease, which is similar to what has been previously described 
(Fig. 2.1A, Table 2.1). The mice initially develop a short phase of disease with lower 
clinical scores that progressed into more severe symptoms of EAE.  These animals were 
considered to be part of the severe EAE group.  The other 14 mice (31.1% of the mice 
experimentally induced with EAE) showed a milder form of the disease which can be 
characterized by the initial mild disease severity that did not progress later into more 
severe scores as seen in the severe EAE group.  These mice exhibited average scores 
much less than the severe EAE group and therefore considered to be the mild EAE group 
(Fig. 2.1A, Table 2.1).  One animal in the mild EAE group did exhibit a clinical score of 
2 on day 34; however, it did not progress into a more severe form of EAE and therefore 
was still considered in part of the mild EAE group. 
Scores for both the severe EAE group as well as the mild EAE group exhibited an 
initial phase of disease ranging from day 9 to day 35 with scores averaging between 0.5 
and 1.  At day 35, the clinical scores the severe EAE group progressed into the more 
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severe clinical score range and did not exhibit any signs of remission.  The mild EAE 
group, however, did exhibit signs of a remission post day 35 (Fig. 2.1A).  The area under 
the curve was greater for the severe EAE group as compared to both the mild EAE group 
as well as the no EAE group (Fig. 2.1B).  The no EAE group were mice that were not 
challenged with EAE and therefore exhibited no symptoms of EAE (Fig. 2.1A).  There 
also was no significant difference between the area under the curve for the no EAE group 
and the mild EAE group (Fig. 2.1B).  Even though the severity of the disease differed 
between the severe EAE group and the mild EAE group, there was no difference in the 
onset of EAE between these groups (Fig. 2.1C). 
 The body weights of every animal were monitored and recorded weekly.  There 
was no significant difference in body weight between all of the groups (data not shown).  
However, when the percentage of the initial weight was compared based on the form of 
disease that developed (mild vs. severe), we observed a significant decrease in weight 
gain in the severe EAE group versus the no EAE control group (Fig 2.1D). 
To assess whether or not disease severity affected the composition of the gut 
microbiota, we longitudinally evaluated the mice at each time point of fecal pellet 
collection (days 0, 14, 30, and 58 post EAE induction) and correlated this with the 
severity of EAE symptoms for each mouse.  These groups consisted, again, of the control 
no EAE group, the mild EAE group, and the severe EAE group. The clinical scores at the 
times of the collection are shown in Figure 2.2A.  Of all the stool samples collected, we 
analyzed 15 of the mice.  We chose mice that were never caged with mice belonging to 
mice of other experimental groups.  To generate relative abundances on each taxonomical 
level, 16S rRNA gene amplicon sequencing was used.  To assess whether disease 
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severity affected stool microbial composition, we analyzed the similarity between each 
individual animal analyzed. To establish a genetic background baseline to compare 
deviations in the stool microbial composition, we compared stool collected prior to EAE 
induction on day 0.  The analysis was conducted at the genus level by ordination analysis 
using nonmetric dimensional scaling (NMDS) in 2 dimensions (Fig. 2.2B).  We used the 
NMDS combination that yielded the lowest stress.  Stress is defined as deviations 
between the original dissimilarity of samples generated after the simplified combination 
of the original taxa levels.  After the NMDS analysis, we used the ADONIS multivariate 
non-parametric ANOVA and ran the ADONIS analysis with 10,000 permutations to 
obtain a distribution of p-values per comparison.  No significant differences were 
observed between the groups at this time point of day 0 (p = 0.895) (Fig. 2.2 and Table 
2.2).  Further, when the groups were compared individually (no EAE vs. mild EAE, no 
EAE vs. severe EAE, and mild EAE vs. severe EAE) there were no significant 
differences observed (Table 2.2). 
 The Shannon diversity index, a measure of taxa richness and evenness, of the 
stool samples isolated from mild EAE group on day 14 was higher when compared to the 
no EAE group (Fig. 2.2C; p = 0.0267).  It also showed a trend towards elevation (p = 
n.s.) in the severe EAE mice when compared to the no EAE group (Fig. 2.2C).  When 
comparing the amount of observed taxa at the species level between severe EAE mice 
and no EAE mice, there was a significant reduction at day 58 indicating that a lower level 
of species was identified in EAE mice at the end of the experiment (Fig. 2.2C; p = 
0.0234). 
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 We next compared the overall composition of the gut microbiome of the three 
different groups on days 14, 30, and 58 at the genus level as well by 2-dimesional NMDS 
(Fig. 2.3A and Table 2.2).  We started by comparing day 0 for the control no EAE group 
with days 14, 30, and 58.  We noted no significant difference between the gut 
microbiome composition at these various time points (day 0 vs. day 14: p = 0.0961; day 0 
vs. day 30: p = 0.0960; day 0 vs day 58: p = 0.0962).  This was also true when comparing 
day 14 with day 30 and day 58 both with p-values of 0.0962 (graph not shown).   
When comparing the taxa at the genus level on day 14, there were significant 
differences between the overall compositions of the gut microbiome between the control 
no EAE group, the mild EAE group, and the severe EAE group (p = 0.0034) (Fig. 2.3A 
and Table 2.2).  This was also the case between the compositions on day 30 (p = 0.0096) 
(Fig. 2.3A and Table 2.2).  However, there were no significant differences between the 
groups on day 58 (p = 0.1915) (Fig. 2.3A and Table 2.2).   When analyzing the gut 
microbiome between groups at day 14, there were still significant differences; no EAE 
group vs. mild EAE group (p = 0.0406) and no EAE group vs. severe EAE group (p = 
0.0167) (Table 2.2).  Further, on day 14 there also was a significant difference between 
the structure of the gut microbiome of the mild EAE group vs. the severe EAE group (p = 
0.0327) (Table 2.2). 
On day 30, there also was significant differences between the gut microbial 
composition of the control no EAE group vs. the severe EAE group (p = 0.0168) and 
between the mild EAE group vs the severe EAE group (p = 0.0407) but not between the 
control no EAE group vs. the mild EAE group (p = 0.3183) (Table 2.2).  At day 58 post-
EAE induction there were no overall differences between the three groups (p = 0.1915) 
 44 
 
(Fig. 2.3A and Table 2.2).  Similar NMDS analyses and statistical comparison were run 
at every taxonomical level but no significant differences were seen between the gut 
microbial compositions on day 58 (not shown).  From these results we do believe that 
EAE does in fact alter the composition of the gut microbiome in NOD mice.  Further, the 
extent of disease itself seems to alter the composition as well; this is clearly seen when 
examining the severe EAE group vs. the mild EAE group and then further the control no 
EAE group vs. the mild EAE group. 
We next compared the effects of disease progression and severity on the relative 
abundance of genera among the major phyla.  The relative abundances at the genus level 
are shown in Figure 2.3B (average relative abundances for the n = 5 per group and time 
point).  We observed changes in genus-level sequence counts of gut microbiota primarily 
in the early stages of disease.  An undetermined genus of the family Ruminococcaceae 
and the genus Akkermansia from the family Verucomicrobiaceae were increased in the 
severe EAE group vs. the control no EAE group.  The undetermined genus of the family 
Ruminococcaceae differed between the control no EAE group vs. the severe EAE group 
at day 14 (raw p = 0.008, adj. p = 0.17) (Fig. 2.4).  The genus Akkermansia differed 
between the control no EAE group vs. the severe EAE at day 14 as well (raw p = 0.031, 
adj. p = 0.57) (Fig. 2.4).  The opposite was seen with an undetermined genus of the 
family Christensenellaceae the genus Lactobacillus of the family Lactobacillaceae, in 
which there was a decrease in sequence counts for these taxa between the severe EAE 
group vs. the control no EAE group.  The undetermined genus of the family 
Christensenellaceae differed between the control no EAE group vs. the severe EAE 
group at day 14 (raw p = 0.008, adj. p = 0.22) (Fig. 2.4).  The genus Lactobacillus 
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differed between the control no EAE group vs. the severe EAE at day 14 as well (raw p = 
0.008, adj. p = 0.17) (Fig. 2.4). 
When taken together, our results for the retrospective analysis of stool from mice 
suffering from various severities of EAE show that the extent of disease as well as time 
point during disease progression alters the structure of the gut microbiome.  Moreover, 
these alterations can have a direct impact on specific bacterial taxa.  These changes, 
however, are short lived and occur primarily in early more inflammatory stages of 
disease.  Due to the limited number of samples compared, it is possible that our data 
would preclude to put statistical significance on these changes, although interesting 
trends that require further study were observed. 
Using putative metagenomics reads based on using the PICRUSt algorithm 
showed differing functionality in the gut microbiome based on what taxa were altered 
(Fig. 2.5).  The heat-map generated shows that metagenomics functions differed in the 
severe EAE group, but did not in the mild EAE group or the no EAE group.  
Metagenomic function irrelevant to bacterial function were not included (Fig. 2.5).  
Further, metagenomic functions between the various time points of disease were analyzed 
using two-way ANOVA followed by multiple comparisons test (Table 2.3).  Significance 
under a p-value of 0.05 were noted in red.  Taking data from disease severity and stage of 
disease, amino acid metabolism and carbohydrate metabolism were further analyzed 
based on disease severity from stool collected on day 14 (Fig. 2.6). 
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Discussion 
 The understanding of how important the gut microbiome is in context to disease 
has increased dramatically in recent scientific history.  Our work as well as others 
highlights just how important the immunomodulatory nature of the gut microbiome, 
particularly the bacteria, is in the case of progression for experimental animal models of 
CNS autoimmunity.   
In this experiment, we show and characterize just how disease itself (specifically 
EAE) alters the gut microbiome.  Our results indicated that gut microbiota altered early in 
mice that developed EAE as opposed to those that did not.  Statistical analyses were 
unable to detect specific deviations in specific bacterial genera associated with disease-
induced dysbiosis.  The trends show preliminary data that specific taxa that exhibit 
immunomodulatory effects as well as regulate disease progression are affected.  The 
genus Lactobacillus was reduced (raw p = 0.008, adjusted: n.s.).  Lactobacillus is known 
for promoting immunomodulation and a mixture of Lactobacillus spp. has been shown to 
promote protection against EAE in mice.19  This reduction in Lactobacillus could have a 
profound impact on disease severity as well as progression.  Another genus that was 
reduced in the severe EAE mice was Christensenellaceae.  Very little is known about the 
functionality of Christensenellaceae and its role in the gut microbiome.  This, in turn, 
makes it quite interesting that it was reduced in the EAE murine model.  On the other 
hand, the genus Akkermansia as well as an unspecified genus of the family 
Ruminococcaceae were increased in the severe EAE mice.  Interestingly enough, a study 
reported that the fecal transplantation of stool from MS patients into mice caused the 
spontaneous development of EAE.3  The stool obtained from those MS patients had 
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elevated levels of Akkermansia as well.3  These findings are interesting especially when 
considered in the context to our study. 
 Additionally, we explored how alterations in gut microbiota would impact how 
the gut microbiota functions.  To do this, we utilized PICRUSt as part of the pipeline 
analysis through Nephele by the NIH.  Part of the analysis generated metagenomics reads 
that could be quantified between the experimental groups.  The severe EAE group had a 
different function when compared to the mild EAE group and no EAE group (Fig. 2.5).  
Additionally, the difference between microbiome function was noted specifically during 
day 14 post EAE induction (Table 2.3).  We then further were interested in amino acid 
metabolism as well as carbohydrate metabolism due to their immunogenic importance.  
We noted that there was an increase in gene expression for amino acid metabolism and 
carbohydrate metabolism in the severe EAE group when compared to the mild EAE 
group and the control group. 
 The data generated from PICRUSt is putative, but it provides interesting insight to 
how disease severity and disease progression alters the gut microbiome.  The 
composition of the gut microbiome appears to be heavily influenced by both disease 
severity as well as the time point post disease induction.  These structural changes have a 
profound impact on the way the gut microbiome can then function; by reducing bacterial 
populations such as Lactobacillus, but increasing Akkermansia, there appears to be 
changes in how the community behaves.  These perturbations in the gut microbiota must 
have some immunomodulatory impact that might be increasing the extent of 
inflammation in the CNS.  It is unfortunate, however, that the data generated by PICRUSt 
is speculative, but the data can be a used to design further studies.  In this experiment, we 
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noted an increase in amino acid metabolism.  This could hold some functional importance 
due to the fact that gamma-aminobutyric acid (GABA) is a derivative of amino acids, and 
its production is dependent on the gut microbiota.20  Moreover, GABA levels has also 
been noted to be reduced in MS patients.  Additionally, our lab is currently evaluating the 
effects of GABA on EAE and determining its efficacy in reducing disease severity; 
although speculative, perhaps the increase in amino acid metabolism could be reducing 
GABA levels in the EAE mice. 
 In conclusion, this study aimed at exploring the extent in which EAE altered the 
composition of the gut microbiome in NOD mice.  This experiment further strengthens 
the notion that the gut microbiome plays a critical role in disease pathology.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
 
References 
1. Danikowski, K.M., Jayaraman, S., Prabhakar, B.S. 2017. Regulatory T cells in 
multiple sclerosis and myasthenia gravis. J Neuroinflammation. 14: 117. 
2. Cekanaviciute, E., Yoo, B.B., Runia, T.F., Debelius, J.W., Singh, S., Nelson, C.A., 
KAnner, R., Bencosme, Y., Lee, Y.K., Hauser, S.L., Crabtree-Hartman, E., Sand, I.K., 
Gacias, M., Zhu, Y., Casaccia, P., Cree, B.A., Knight, R., Mazmanian, S.K., Baranzini, 
S.E. 2017. Gut bacteria from multiple sclerosis patients modulate human T cells and 
exacerbates symptoms in mouse modles. PNAS. 114(40):10713-718. 
3. Berer, K., Gerdes, L.A., Cekanaviciute, E., Jia, X., Xiao, L., Xia, Z., Liu, C., Klotz, L., 
Stauffer, U., Baranzini, S.E., Kümpfel, T., Hohlfeld, R., Krishnamoorthy, G., Wekerle, 
H. 2017. Gut microbiota from multiple sclerosis patients enables spontaneous 
autoimmune encephalomyelitis in mice. PNAS. 114(40):10719-724. 
4. Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., Coron, E., 
Bruley des Varannes, S., Naveilhan, P., Nguyen, J.M., Neunlist, M., Derkinderen, P. 
2013. Colonic inflammation in Parkinson’s disease. Neurobiol Dis. 50:42-8. 
5. Braak, H., Rub, U., Gai, W.P., Del Tredici, K. 2003. Idiopathic Parkinson’s disease: 
possible routes by which vulnerable neuronal types may be subject to nueroinvasion by 
an unknown pathogen. Journal of neural tansmission. 110:517-536. 
6. Verbaan, D., Marinus, J., Visser, M., van Rooden, S.M., Stiggelbout, A.M., van Hilten, 
J.J. 2007. Patient-reported autonomic symptoms in Parkinsons’s disease. Nuerology. 
69:333-341.  
 50 
 
7. Ochoa-Repáraz, J., Mielcarz, D.W., Ditrio, L.E., Burroughs, A.R., Foureau, D.M., 
Haque-Begum, S., Kasper, L.H. 2009. Role of Gut Commensal Microflora in the 
Development of Experimental Autoimmune Encephalomyelitis. J Immunol. 
183(10):6041-50. 
8. Basso, A.S., Frenkel, D., Quintana, F.J., Costa-Pinto, F.A., Petrovic-Stojkovic, S., 
Puckett, L., Monsonego, A., Bar-Shir, A., Engel, Y., Gozin, M, et al. 2008. Reversal of 
axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin 
Invest. 118(4);1532-43. 
9. Encinas, J.A., Wicker, L.S., Peterson, L.B., Mukasa, A., Teuscher, C., Sobel, R., 
Weiner, H.L., Seidman, C.E., Seidman, J.G., Kuchroo, V.K. 1999. QTL influencing 
autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing Il2. Nat 
Genet. 21(2):158-60. 
10. Levy, H., Assaf, Y., Frenkel, D. 2010. Characterization of brain lesions in a mouse 
mofel of progressive multiple sclerosis, Exp Neurol. 226(1):148-58.  
11. Ochoa-Repáraz, J., Mielcarz, D.W., Wang, Y., Begum-Haque, S., Dasgupta, S., 
Kasper, D.L., Kasper, L.H. 2010 A polysaccharide from the human commensal 
Bacteroidetes fragilis protects against CNS demyelinating disease. Mucosal Immunol. 
3(5):487-95. 
12.McInerney, M.F., Pek, S.B., Thomas, D.W. 1991. Prevention of insulitis and diabetes 
onset by treatment with complete Freund’s adjuvant in NOD mice. Diabetes. 40:715-25; 
PMID:2040388. 
 51 
 
13. Sadelain, M.W., Qin, H.Y., Lauzon, J., Singh, B. 1990. Prevention of type 1 diabetes 
in NOD mice by adjuvant immunotherapy. Diabetes. 39:583-9; PMID:2139617. 
14. Qin, H.Y., Sadelain, M.W., Hitchon, C., Lauzon, J., Singh, B. 1993. Complete 
Freund’s adjuvant-induced T cells prevent the development and adoptive transfer of 
diabetes in non-obese diabetic mice. J Immunol. 150:2072-80; PMID:8436836. 
15. McMurdie, P.J., Holmes, S. 2013. Phyloseq: an R package for reproducible 
interactive analysis and graphics of microbiome census data. PLoS One. 8(4):e61217.; 
PMID23630581. 
16. Minchin, P.R. 1987. An evaluation of the relative robustness of techniques for 
ecological ordination. Minchin, P.R. Vegetatio. 69:89-107. 
17. Oksanen, J., Blanchet, F.G., Kindt, R., Legendre, P., Minchin, P.R., O’Hara, R.B., 
Simpson, G.L., Solymos, P., Stevens, M.H.H., Wagner, H. Vegan: Community Ecology 
Package. R package 2.2.1. http://www.worldagroforestry.org/publication/vegan-
community-ecology-package-r-package-vegan-ver-22-1. 
18. Anderson, M.J. 2001. A new method for non-parametric multivariate analysis of 
variance. Austral Ecology. 26:32-46. 
19. Lavasani, S., Dzhambazov, B., Nouri, M., Fåk, F., Buske, S., Molin, G., Thorlacius, 
H., Alenfall, J., Jeppsson, B., Weström, B. 2010. A Novel Probiotic Mixture Exerts a 
Therapeutic Effect on Experimental Autoimmune Encephalomyelits Mediated by IL-10 
Producing Regulatory T Cells. PLoS One. 5(2):e9009. 
 52 
 
20. Laroute, V., Yasaro, C., Narin, W., Mazzoli, R., Pessione, E., Cocaign-Bousquet, M., 
Loubière, P. 2016. GABA Production in Lactococcus lactis Is Enhances by Arginine and 
Co-additon of Malate. Front Microbiol. 7: 1050. 
 
  
 53 
 
Figures and Tables 
 
Table 2.1. Number of mice used, number and percentage of mice that developed mild and severe 
EAE, and day of disease onset.  
 
 
Figure 2.1. Active EAE induces a progressive CNS disease in mice. EAE was induced in NOD 
mice with a subcutaneous injection of MOG35-55 emulsified in CFA and 2 doses of pertussis toxin 
(day 0 and 1) given intraperitoneally. Disease was induced in a total of 45 mice in 3 independent 
experiments. 25 NOD mice were used as controls (no EAE). A) Graph depicts EAE clinical 
scores using a 0-5 scale from one of 3 experiments performed (no EAE n = 5; EAE-induced, n = 
15). Scores were compared by one-way ANOVA analysis followed by multiple comparisons test 
(no EAE vs. mild EAE, mild EAE vs. severe EAE, and no EAE vs. severe EAE: p < 0.001). B) 
Graphs indicate the area under the curve pf the clinical scores of all mice from the 3 experimental 
groups: no EAE n = 25, mild EAE n = 14, and severe EAE n = 31 mice. The area under the 
curves were compared by one-way ANOVA followed by multiple comparisons test. C) Day of 
EAE onset for all mice from the 3 experimental groups, mild EAE n = 14 and severe EAE n = 31 
mice, compared by student’s t-test. D) Body weights of no EAE, mild EAE, and severe EAE mice 
from one of the three experiments performed (no EAE n = 5, mild EAE n = 5, severe EAE n = 
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10). Percentages of body weights were compared by two-way ANOVA followed by multiple 
comparison test (no EAE vs severe EAE: ***, p < 0.001). 
 
 
Figure 2.2. Composition of the microbiome at day 0, α diversity and species richness during 
disease. Stool samples analyzed from no EAE control mice  (n = 5), mice that developed mild 
disease  (n = 5), and mice that developed severe EAE (n = 5). A) Samples were collected from all 
NOD mice. Clinical scores (mean +/- SEM) of mice at each time point of fecal collection (day 0, 
14, 30, and 58 post-EAE induction) were compared by two-way ANOVA. B) To examine the 
compositional heterogeneity of the microbial communities found in the three groups, we used 
non-metric dimensional scaling (NMDS) in R to ordinate the microbial communities of samples 
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based on the Bray-Curtis dissimilarity index using QIIME after the 16S rRNA gene sequencing 
analysis of stool samples, using the phyloseq package. Shown are the NMDA graph for the genus 
taxonomical level of OTUS identified in the analysis at day 0. The statistical comparison was 
performed using the permutational Multivariate Analysis of Variance Using Distance Matrices, 
ADONIS, in the vegan package. C) Shannon index of α diversity and observed species measure 
in the 3 experimental groups compared by one-way ANOVA.  
 
 
Table 2.2. Averages of the p-values obtained after 10,000 different ADONIS analysis of NMDS 
graphs for the genus level shown in Fig. 2 and 3A. 
 
Figure 2.3. Early stages of EAE significantly affect the overall composition of the gut 
microbiome. A) NMDS analysis for the genus taxonomical level of OTUs identified in the 
analysis at day 14, 30, and 58. B) Relative abundances observed in analysis of the gut microbiota 
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at the genus level. The bar graph represents the average of relative frequencies per group (n = 5) 
per time point for abundances equal or above 1%. 
 
 
Figure 2.4. Taxonomical differences between the no EAE, mild EAE, and severe EAE groups.  
OTUs observed were compared at the genus level using the non-parametric Wilcoxon Rank-Sum 
test was used. 
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Figure 2.5. A heat-map was generated based on the magnitude of metagenomics reads based on 
disease severity from pellets obtained on day 14 post EAE induction.  From the fecal pellets, 16S 
rDNA amplicon sequencing was performed and OTUs were generated using Nephele through the 
NIH.  Additionally, PICRUSt annotations of putative metagenomics function were applied to the 
OTUs after being normalized. 
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Table 2.3. Metagenomic functions differed on day 14 post EAE induction.  Utilizing PICRUSt, 
metagenomic annotations obtained from mice on day 0, day 14, day 30, and day 58 were 
generated.  Using two-way ANOVA followed by multiple comparisons test, each metagenomics 
function was analyzed.  Significance was considered for p-values below 0.05 and are denoted in 
red. 
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Figure 2.6. Carbohydrate and amino acid metabolism differed between the severe EAE group on 
day 14.  Using two-way ANOVA followed by multiple comparisons test, significance was noted 
(p < 0.05). 
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Chapter 3: Exploring Outcomes of Altering the Gut Microbiome in a murine model of 
Multiple Sclerosis 
Introduction 
The use of antibiotics to target the gut microbiome for therapeutic merit has been 
explored in the case Type 1 Diabetes, Fulminant Ulcerative Colitis, and experimental 
autoimmune uveitis.1-3  Utilizing antibiotic cocktails to modulate intestinal microbiota 
caused changes in disease severity. In the model of experimental autoimmune uveitis, the 
expression of CD4+Foxp3+ Treg cell populations was increased while a reduction in IL-
17 producing Th17 cells was observed.3  These results, especially in the case of 
experimental autoimmune uveitis, suggests insight that antibiotic interventions may 
confer protection against symptoms of EAE, a model disease for MS, in NOD mice.  
Increased levels of Th17 cells and reduced levels of Tregs have also been noted in MS.4,5 
EAE has previously been explored in the context of antibiotic intervention.  A 
study by Ochoa-Repáraz et al. demonstrated that broad-spectrum antibiotic interventions 
disrupted the balance between pro- and anti-inflammatory responses by modulating Treg 
cell populations.6  Additionally, Yokote et al. reported similar findings but in Natural 
Killer T cell populations.7  These experiments analyzed the impact of antibiotic 
intervention on modulation of EAE in SJL as well as C57 mice.  However, to the best of 
our knowledge, the impact of antibiotics on symptoms of EAE in NOD mice remains 
unknown. 
NOD mice demonstrate a more chronic, long-term version of EAE whereas SJL 
and C57 mice exhibit a short, yet severe, course of EAE.  By utilizing NOD mice as 
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opposed to SJL or C57 mice, it is possible to elucidate the impact intestinal microbiota 
plays at various points in EAE progression.  Additionally, utilizing NOD mice could also 
provide novel insight into a potential therapeutic window for disease modulation; by 
demonstrating when antibiotics have the most prominent effect on disease progression, it 
is possible to infer the ideal time point in which therapeutics could have the most 
beneficial effect. 
We propose to explore the role antibiotic intervention plays on EAE modulation 
at various time points of disease.  Because of the heightened inflammation occurring in 
the early stages of EAE, we hypothesize that early antibiotic intervention would have the 
highest beneficial impact on disease severity.  The later stages of EAE are defined as 
being more neurodegenerative and therefore antibiotic interventions during the middle 
and late stages of EAE are predicted to have lower impacts on modulating EAE severity.  
Further, it is also hypothesized that antibiotic interventions would increase Treg cell 
populations based on evidence obtained from Ochoa-Repáraz et al. in 2009.6 
Materials and Methods 
Mice and Treatments 
Ten-week old female NOD ShiLt (NOD/ShiLt) mice obtained from the Jackson 
Laboratories were utilized for the experiment.  All aspects of animal use and care were 
conducted in accordance with the institutional policies for animal health and well-being 
under Eastern Washington University. 
 Mice subjected to oral antibiotic treatment were given drinking water with 
neomycin (1 g/L) (Fischer Bioreagents, BP2669-25), vancomycin (0.5 g/L) (Fischer 
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Bioreagents, BP2958-1), metronidazole (1g/L) (Acros Organics, 210340050), and 
ampicillin (1 g/L) (Fischer Bioreagents, BP1760-25) for 2 weeks. Control mice received 
standard drinking water, and three different treatment windows were used depending on 
the experiment: 1) day 0 of EAE induction to day 14. 2) day 30 to day 44, or 3) day 69 to 
day 83.  Body weights were measured on day 0 of EAE induction (at the initiation of 
treatment with antibiotics), every 3 days during antibiotic treatment, and weekly 
following the termination of antibiotic treatment. 
EAE induction 
EAE was induced using the Hooke KitTM for EAE induction (Hooke Laboratories, 
EK-2110) containing 200 µg MOG35-55 emulsified in 200 µl of complete Freund’s 
adjuvant (CFA).  Each mouse was initially challenged with a single subcutaneous 
challenge.  On days 0 and 1 post-challenge, each mouse received 400 ng of Bordetella 
pertussis toxin intraperitoneally (List Biological Laboratories, Campbell, CA; provided 
with the Hooke KitTM for EAE induction).  Mice we monitored and the disease 
progression was scored daily as previously described: 0, clinically normal; 0.5, limp tip 
of the tail (when picked up by the base of the tail, the tail still has tension except for the 
tip); 1, limp tail (no tail tension observed); 1.5, limp tail and inhibition of the hind legs 
with a slight wobble when the individual walks; 2, limp tail and hind leg weakness, the 
wobble in each step is more pronounced, mouse exhibits poor balance;2.5, limp tail, and 
the hind legs drag; mouse exhibits poor balance; 3, limp tail, hind legs exhibit complete 
paralysis, or limp tail with one front leg and one hind leg exhibiting complete paralysis; 
3.5, limp tail, hind legs exhibit complete paralysis, and mouse can move, but if placed on 
its side it cannot right itself back up; 4, limp tail, hind legs exhibit complete paralysis, the 
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front legs are starting to show signs of paralysis, and the mouse is moving minimally but 
still appears to be alert and eating; 5, limp tail, hind legs exhibit complete paralysis, 
mouse exhibits minimal movement in front legs, and the mouse expresses minimal or no 
reaction to contact.8  In accordance with IACUC policies, mice exhibiting a score of 3.5 
or higher were sacrificed with primary chemical euthanasia via carbon dioxide 
asphyxiation followed by secondary physical euthanasia via cervical dislocation.  The 
first two days of concurrent scores of 0.5 or higher were considered and documented as 
the onset of disease per individual.  Type 1 diabetes will spontaneously develop in NOD 
mice at week 14-20 of age unless CFA is administered.9-11  For breeding purposes, we 
administered CFA to the breeding pairs to prevent the onset of insulitis.  Diabetic mice 
were not treated with CFA or MOG35-55. 
Cell preparation and flow cytometry 
Single cell lymphocyte preparations from Peyer’s patches were stained using 
conventional methods.  A live/dead fixable fluorescence-labeled viability dye (BD 
Biosciences, 564407) was used in all staining protocols, and samples were gated on 
viable cells for subsequent analysis.  Cell subsets were analyzed using fluorochrome-
conjugated mAbs against T cell antigens CD3 (BD PharMingen, 553062), CD4 (BD 
PharMingen 553052), and CD39 BioLegend, 143804).  Intracellular staining for Foxp3 
was performed using fluorochrome labeled anti-Foxp3 mAb (clone FJK-16s; 
eBioscience, 175773-82).  Flow cytometric results were acquired using BD Accuri C6 
(BD Biosciences, San Jose, CA).  Data was analyzed using FloJo software (FloJo LLC., 
Ashland, OR). 
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Statistical analysis 
Parametric and non-parametric t-tests and one-way ANOVA followed by the Kruskal-
Wallis comparisons of multiple groups was applied to show differences in flow 
cytometric analysis.  Two-way ANOVA followed by multiple comparisons tests were 
used to compare the scores of EAE and EAE-ABX mice.  In addition, area under the 
curve analysis followed by Mann-Whitney tests were used to compare scores of EAE and 
EAE-ABX mice.  Weights were compared by two-way ANOVA followed by multiple 
comparisons test.  To compare severity index, the Mann-Whitney test was used (p-values 
< 0.05, <0.01, <0.001, and <0.0001 were indicated). 
Results 
Previous work has documented the effects of the gut microbiota in regard to regulating 
the progression of acute EAE when SJL and B6 mice were treated orally with broad 
spectrum antibiotics before the induction of EAE.6,7 Ochoa-Repáraz et al. showed that 
treatment with broad-spectrum antibiotics altered the balance of regulatory and pro-
inflammatory responses in mice with EAE and that regulatory T cells (Tregs) were 
responsible for the protection achieved via microbiota modulation.6  Nakamura et al. 
showed similar results in the case of the autoimmune uveitis.3  Additionally, Yokote et al. 
reported similar findings but suggested that a different cell population was responsible.7  
Our experiment wanted to evaluate whether broad-spectrum antibiotics would affect the 
progression of the secondary, more severe, stages of EAE in NOD mice.  The average 
clinical scores of the antibiotic treated mice were significantly reduced at multiple time 
points after day 40 (Fig. 3.1A).  Analyzing the area under the curves showed a significant 
reduction in clinical scores of mice treated with the antibiotic cocktail when compared to 
 65 
 
control mice (Fig. 3.1B; p = 0.0162).  Additionally, the treatment with antibiotics also 
delayed the onset of disease (Fig. 3.1C; p = 0.0005) and reduced the overall severity 
index when compared to control mice (Fig. 3.1D; p = 0.008).  Because of the unintended 
impacts to animal health from broad-spectrum antibiotic exposure, the weight of each 
animal was monitored weekly.  At day 6 of treatment, we observed a significant 
reduction in body weight of antibiotic treated mice when compared to control mice (Fig. 
3.1E).  At day 10, the weights recovered and no overall significant differences were 
observed when comparing the area under the curve (not shown; p = 0.7295).  Flow 
cytometric analysis showed that the frequency of Foxp3+ Tregs increased in the Peyer’s 
patches during EAE (Fig. 3.1F).  We also noticed similar increases in CD39+ T cells as 
well as Foxp3+CD39- Tregs. 
 We then compared the ability of orally administered broad-spectrum antibiotics to 
reduce the severity of EAE when administered after the onset of disease.  Using mice that 
survive the initial wave of CNS inflammation, we treated mice with antibiotics from day 
30 to day 44 or day 69 to day 83 post EAE challenge.  Again, control mice received 
normal drinking water.  As a whole, the mice that received antibiotics during later stages 
of disease showed a mild improvement in clinical scores, but the difference was not 
statistically significant (Fig. 3.2).  This indicates that early intervention of gut microbiota 
manipulation can affect the progression of EAE in NOD mice. 
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Discussion 
Our work, as well as others, highlights just how important the immunomodulatory 
nature of the gut microbiome, particularly the bacteria, is in the case of disease 
progression for experimental animal models of autoimmunity.  In this experiment, we 
evaluated the gut microbiome and how it modulates the severity of disease (in this case, 
EAE). 
 Our results indicate that disease progression is significantly altered when mice 
received broad-spectrum antibiotics orally.  Two weeks of treatment also significantly 
delayed the onset of EAE as well (Fig. 3.1).  Moreover, despite the long nature of EAE in 
NOD mice, the short therapeutic window of the early stages of disease can reduce the 
severity of the second phase of disease when intervention is undertaken early in disease 
development.  This is logical in the context of the composition of the gut microbiome, as 
well as more inflammatory nature of the first phase of EAE.12  The second phase of EAE 
in NOD mice is more neurodegenerative and, therefore, later therapeutic intervention 
with antibiotics would be predicted to have a diminished impact on disease modulation.12 
 We observed that antibiotic intervention at later time points of the disease (day 
30-44 as well as day 70-84) did not have a significant impact on disease severity (Fig. 
3.2).  This is largely attributable to the fact that alterations in the gut microbiome are not 
as large or important at this stage of disease.  In one study, on day 58 post EAE induction 
in NOD mice there was no significant differences in the gut microbiota structure between 
severely ill EAE mice, mildly ill EAE mice, and mice not subjected to EAE.12  This may 
reflect the observation that, at this point, the inflammatory phase of disease has passed, 
and thus is logical that altering the gut microbiome would have no major impact on 
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disease severity; at this point, the onset of neurodegeneration is underway.  Additionally, 
we demonstrated that the functional differences in the gut microbiome were noted on day 
14 post EAE induction as opposed to day 30 or day 58.  This further supports the notion 
that the antibiotics were unlikely to have a profound effect on disease modulation during 
late stages of disease. 
In conclusion, this study was geared to explore the extent in which the gut 
microbiome modulates disease in NOD mice.  This experiment further strengthens the 
notion that the gut microbiome plays a critical role in disease pathology.   
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Figures and Tables 
 
Figure 3.1.  Early treatment with antibiotics reduces the severity of EAE in NOD mice. EAE was 
induced in NOD mice that were treated with antibiotics administered in the drinking water from 
day 0 to 14 or given normal drinking water as a control. A) EAE clinical scores are shown from 
one or two independent experiments (n = 5), for a total of n = 8 per group. Comparisons were 
made using a two-way ANOVA followed by multiple comparisons test (*, p < 0.05). Graphs 
indicate the area under the curve as calculated by Prism (B; n = 5 for the experiment depicted in 
panel A), the day of EAE onset (C), and the severity index (D). Panels C and D depict values 
obtained for all mice combined between the 2 experiments (n = 8). Significance was measured 
using Mann-Whitney test. E) Body weights shown from one or two independent experiments for 
a total of n = 8 per group. Two-way ANOVA followed by multiple comparisons test (**, p < 
0.01; ***, p < 0.001). F) Graphs indicate frequencies of Tregs using flow cytometric analysis of 
live CD4+ T cells in the Peyer’s patches based on expression of Foxp3 and CD39 (n = 5 per 
group). Comparisons were made using a two-way ANOVA followed by multiple comparisons 
test (*, p < 0.05; **, p < 0.001). 
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Figure 3.2.  Late treatments with antibiotics does not reduce the severity of EAE in NOD mice. 
EAE was induced in NOD mice that were treated with antibiotics administered in the drinking 
water from day 30 to day 44 as well as day 70 to day 84. A) EAE clinical scores are shown 
from one or two independent experiments (n = 5), for a total of n = 8 per group. Two-way 
ANOVA followed by multiple comparisons test. Graphs indicate the area under the curve as 
calculated by Prism (B; n = 5 for the experiment depicted in panel A). Significance was measured 
using Mann-Whitney test. C) EAE clinical scores are shown from one or two independent 
experiments (n = 5), for a total of n = 8 per group. Two-way ANOVA followed by multiple 
comparisons test. Graphs indicate the area under the curve as calculated by Prism (C; n = 5 for 
the experiment depicted in panel D). Significance was measured using the Mann-Whitney test. 
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Chapter 4: Assessing the protective effects of an anti-inflammatory, genetically 
modified, Probiotic strain of Lactococcus lactis in a murine model of Multiple Sclerosis 
Introduction 
Tolerance is the control that our immune system has in the balance between 
overactive or underactive immune cells.  The immune system also must balance 
inflammatory responses and anti-inflammatory responses, in conjunction with tolerance, 
to ensure that the body only attacks foreign or pathogenic material but not the residential 
microbes or self-components. If these mechanisms fail, the result is autoimmunity.  
Autoimmune diseases are diseases in which an exaggerated immune response eventually 
leads to immune system failure and an inability to distinguish self from non-self.  The 
microbiome has a clear relationship with the immune system by influencing the balance 
of immune responses that control autoimmune diseases1; the immune system and 
autoimmune diseases share a bidirectional relationship with the gastrointestinal bacteria 
in an individual.2  The disease state shapes the biodiversity and composition of 
gastrointestinal bacteria, and these bacteria help regulate and modulate the host’s immune 
system.1 
Using a MS model known as Experimental Autoimmune Encephalomyelitis 
(EAE) in Non-Obese Diabetic (NOD) mice, we previously showed that disease 
progression is associated with reduction in certain microbial taxa.2  When antibiotics 
were orally utilized after 14 days post disease induction, the disease severity was 
attenuated.2  When the gut microbial composition was analyzed, there was a severe 
reduction in Lactobacillales found in the guts of non-treated micel  This suggests a 
 73 
 
connection between the gut microbiome and autoimmune diseases as a bi-directional 
relationship.   
In terms of treatment options for relapse-remitting MS (RRMS) patients, there are 
commercial drugs already available. However, therapeutics are not efficacious enough 
and come with a wide range of mild to severe side effects.  Furthermore, there currently 
are no options available for secondary progressive MS (SPMS) treatment.3  Thus, new 
and safer treatment options are needed.  Our preliminary data suggests a focus on the 
order Lactobacillales would be prudent, since it is reduced significantly during an early 
therapeutic window.4,5 
Previous experiments have been performed to induce oral tolerance, or 
immunomodulation, via the oral introduction of antigens.4-6  Kasarello et al. used 
Lactococcus lactis to deliver self-antigens by inserting the genes into the L. lactis 
bacterium and found evidence that this methodology is useful for promoting oral 
tolerance.5  What is problematic, however, is that this experiment also used self-antigens 
from myelin tissue.5  In a clinical setting there is a reason of concern with the notion of 
treating MS patients with a self-antigen which could induce harm, and likely would not 
gain IRB-approval.  By engineering the expression of CFA/I fimbria, we eliminate the 
use of self-antigens for oral tolerance and provide a novel and safe approach to achieving 
oral tolerance. 
Because of the potential connection between the reduction in disease severity and 
the presence of Lactobacillus, MS becomes a target disease to investigate using 
Lactobacillus.  The Pascual laboratory at the University of Florida, has developed a 
genetically modified form of Lactococcus lactis to express a Colonizing Factor Antigen I 
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(CFA/I) fimbriae which has been shown to confer protection from other autoimmune 
diseases such as rheumatoid arthritis.7  MS has not been explored with this approach.  
CFA/I fimbriae modulates the immune system by inducing T regulatory cells (Tregs) in 
an ectoenzyme CD39 dependent fashion.8  This immunomodulatory induction of Tregs 
by the CFA/I fimbriae is a central focus of our current design. Choosing the CFA/I 
fimbriae as a target antigen is ideal since the antigen is foreign and non-myelin in nature.  
We intend to utilize the CFA/I genetically modified L. Lactis bacterium to induce oral 
tolerance by performing oral gavage on EAE mice during the therapeutic window in 
which the presence of Lactobacillus is known to be reduced.  We propose to explore the 
immunomodulation of SPMS in the C57 murine model via utilization of a predesigned 
probiotic Lactococcus lactis–CFA/I (L. lactis-CFA/I). We hypothesize that the oral 
treatment of L. lactis–CFA/I will reduce the severity of disease in EAE mice (reduced 
EAE scores). 
 
 
 
 
 
 
 
 
 75 
 
Materials and Methods 
Mice and Treatments 
Ten-week old female NOD C57BL/6 mice obtained from the Jackson 
Laboratories were utilized for the experiment.  All aspects of animal use and care were 
conducted in accordance with the institutional policies for animal health and well-being 
under Eastern Washington University. 
EAE induction 
EAE was induced using Hooke KitTM for EAE induction (Hooke Laboratories, 
EK-2110) containing 200 µg MOG35-55 emulsified in 200 µl of complete Freund’s 
adjuvant (CFA).  Each mouse was initially challenged with a single subcutaneous 
challenge.  One days 0 and 1 post-challenge, each mouse received 400 ng of Bordetella 
pertussis toxin intraperitoneally (List Biological Laboratories, Campbell, CA; provided 
with the Hooke KitTM for EAE induction).  Mice we monitored and the disease 
progression was scored daily as previously described: 0, clinically normal; 0.5, limp tip 
of the tail (when picked up by the base of the tail, the tail still has tension except for the 
tip); 1, limp tail (no tail tension observed); 1.5, limp tail and inhibition of the hind legs 
with a slight wobble when the individual walks; 2, limp tail and hind leg weakness, the 
wobble in each step is more pronounced, mouse exhibits poor balance;2.5, limp tail, and 
the hind legs drag; mouse exhibits poor balance; 3, limp tail, hind legs exhibit complete 
paralysis, or limp tail with one front leg and one hind leg exhibiting complete paralysis; 
3.5, limp tail, hind legs exhibit complete paralysis, and mouse can move, but if placed on 
its side it cannot right itself back up; 4, limp tail, hind legs exhibit complete paralysis, the 
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front legs are starting to show signs of paralysis, and the mouse is moving minimally but 
still appears to be alert and eating; 5, limp tail, hind legs exhibit complete paralysis, 
mouse exhibits minimal movement in front legs, and the mouse expresses minimal or no 
reaction to contact.9  In accordance to IACUC policies, mice exhibiting a score of 3.5 or 
higher were sacrificed with primary chemical euthanasia via carbon dioxide asphyxiation 
followed by secondary physical euthanasia via cervical dislocation.  The first two days of 
concurrent scores of 0.5 or higher were considered and documented as the onset of 
disease per individual. 
Preparation of Lactococcus lactis and Oral Gavages 
For the experiment, two genetically modified strains of Lactococcus lactis were 
obtained from the Pascual laboratory at the University of Florida.  The pBzMM153 strain 
(Lactococcus lactis expressing the CFA/I fimbriae) (L. lactis - CFA/I) and pMSP3535H3 
strain (Lactococcus lactis not expressing CFA/I fimbriae but containing the same plasmid 
vector) (L. lactis empty) were grown at 30oC in DIFCO M17 broth supplemented with 
0.5% glucose with 10µg/mL of erythromycin in a 25 mL flask.  The strains were frozen 
in 100 µL aliquots for subsequent gavages. 
For the gavage treatments, a pre-inoculum was made of 6 mL of M17 DIFCO 
broth supplemented with 0.5% glucose and 1.2µL of erythromycin at a concentration of 
50mg/mL.  The pre-inoculum was inoculated with one 0.1mL aliquot previously frozen.  
The pre-inoculum was incubated overnight at 30oC overnight without shaking.  The next 
morning 3 mL of the pre-inoculum was introduced to 50 mL of pre-warmed fresh M17 
DIFCO broth supplemented with 0.5% glucose and 1.2µL of erythromycin at a 
concentration of 50mg/mL.  The solution was allowed to incubate at 30oC until the 
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optical density was approximately 0.2 to 0.23.  Subsequently, 100µL of nisin was added 
and the bacteria was allowed to incubate for 4 additional hours at 30oC.  The approximate 
CFU level for both L. lactis strains was approximately 30-60 x107 per mL. 
Prior to receiving treatment, each mouse was orally gavaged with sodium 
bicarbonate to neutralize the stomach pH and ensure the L. lactis would survive past the 
stomach and enter the intestines. Subsequently, mice received 5 x 108 CFU of either L. 
lactis - CFA/I, L. lactis empty, or sham (no L. lactis) on day 0, 3, and 7 post EAE 
induction, respectively. 
Statistical Analysis 
Two-way ANOVA analysis followed by multiple comparisons test was used to 
evaluate clinical scores on a daily basis.  We compared L. lactis - CFA/I vs. control 
(sham), L. lactis - CFA/I vs. L. lactis unmodified vector, and L. lactis unmodified vector 
vs. control (sham) daily.  To compare severity index, a one-way ANOVA analysis 
followed by multiple comparisons test was conducted (p-values < 0.05, <0.01, <0.001, 
and <0.0001 were indicated).   
Results 
Lactococcus lactis Expressing the CFA/I antigen confers long-term protection 
against EAE in C57BL/6 Mice 
To assess the efficacy of each treatment in comparison to control (mice received 
PBS solution), we collected clinical scores of disease severity for each mouse every day 
during the progression of disease.  Both the L. lactis - CFA/I as well as the L. lactis 
empty reduced the severity of EAE in mice (Fig. 4.1A).  There were significant 
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differences between the control mice and the L. lactis - CFA/I mice starting on day 10 (p 
< 0.05) (Fig. 4.1A).  Although statistical significance between disease severity in the 
control mice and the L. lactis - CFA/I mice was lost at day 18, statistical significance was 
observed at the termination of the experiment (p < 0.001) (Fig. 4.1A).  From this data, we 
infer that L. lactis - CFA/I conferred long-term protection against EAE that remained 
throughout the experiment even when treatment ended on day 7 post EAE induction. 
Additionally, there was statistically significant differences between the control 
mice and the L. lactis empty mice starting at day 11 (p < 0.05) (Fig. 4.1A).  Statistical 
significance was lost between the control mice and the L. lactis empty mice on day 14, 
but returned for a few days on day 24 (p < 0.005) (Fig. 4.1A).  Ultimately, there was no 
significant difference between the control mice and the L. lactis empty mice at the end of 
the experiment (Fig. 4.1A).  This suggests that there was a degree of protection conferred 
by the L. lactis with an unmodified plasmid but the protection was short-term, especially 
when compared to the L. lactis - CFA group.  On day 28, there was a statistically 
significant difference between the clinical scores of the L. lactis empty mice when 
compared to the L. lactos - CFA/I mice (p < 0.05) (Fig. 4.1A). 
The extent of disease severity in each treatment group was evaluated with pie 
charts (Fig. 4.1B).  Inside each treatment group, mice we grouped by clinical scores 
ranging from 0-1, 1.5-2, 2.5-3, and 3.5-5.  Visually, there are differences between the 
distributions of disease severity in the three treatment groups.  The L. lactis - CFA group 
had scores in the 0-1 range throughout the entire experiment whereas the L. lactis empty 
group no longer had mice with scores of 0-1 on day 28 (Fig. 4.1B).  Interestingly, the 
control group lost individuals with a clinical score of 0-1 on day 14, had individuals with 
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those scores reappear on day 21, and lost them again on day 28 (Fig. 4.1B).  This likely is 
due to natural fluctuations in EAE.  No statistics were conducted on this data set. 
We also compared the severity index for each group.  The severity index is best 
described as being the cumulative scores divided by the number of days with disease 
symptoms.  There was a statistically significant difference between the control mice and 
the L. lactis - CFA mice (p = 0.022) (Fig. 4.1C).  There was no significant difference 
between the severity index of the L. lactis - CFA/I mice and the L. lactis empty mice 
(Fig. 4.1C). 
Discussion 
Lactococcus lactis has been shown to confer protection against EAE in rats 
previously.5  These studies employed self-peptides to induce oral tolerance.  By 
introducing self-antigens, it is possible the probiotic could induce unintended 
complications, especially since autoimmunity has a strong genetic component; being 
genetically susceptible towards autoimmunity may cause alternate autoimmunological 
responses to self-antigens.  The work done by Kasarello et al. was done in rats.5  When 
considering the simplicity of rodent models of autoimmunity in comparison to the 
complications of autoimmunity in humans, using a self-antigen for oral tolerance is not 
feasible. 
 Salmonella vectors containing CFA/I antigens have also been used to induce 
tolerance.11  Moreover, the probiotic conferred production by inducing Treg cell 
populations that, once adoptively transferred into EAE mice, significantly reduced the 
disease severity.11,12  The protection induced was effective and suggests that the induction 
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of oral tolerance is a viable therapeutic option.11  However, the usage of Salmonella as a 
vehicle to deliver antigens is also infeasible in human studies.  Generally, Salmonella is 
associated with pathogenicity.  Therefore, utilizing Lactococcus as a vehicle to deliver 
CFA/I antigens is more attractive.  Lactococcus, and more specifically L. lactis, is 
generally recognized as being safe and edible by the federal Food and Drug 
Administration.  Lactococcus is commonly found in everyday foods like yogurt. 
 In our experiment, we observed a significant difference between the clinical 
severity of EAE in the control mice when compared to the mice receiving L. lactis - 
CFA/I.  The protection conferred by L. lactis - CFA/I was seen starting around day 10 of 
the disease. The protection conferred was maintained throughout the duration of the 
experiment.  A similar outcome was noted between the control mice and the L. lactis 
empty mice.  The extent of protection, however, diminished near the end of the 
experiment around day 26 post-EAE induction.  Interestingly enough, L. lactis has been 
shown to produce gamma-aminobutyric acid (GABA) naturally.13  GABA has been 
shown to be reduced in MS patients; GABA has also been associated with protection in 
MS.  Further, the genus Lactobacillus is also reduced in the gut of NOD mice suffering 
from EAE.2  Therefore, it is expected that L. lactis not expressing CFA/I would, alone, 
confer protection against EAE. We are now evaluating the relevance of the production of 
GABA by L. lactis on EAE protection. 
 When examining the weights between the groups, there were significant 
differences between the percentage weight from before EAE induction and at the end of 
the experiment (data not shown).  As the animals develop EAE they generally lose 
weight.  As a result, examining differences in weight can help provide insight into 
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therapeutic efficacy.  When comparing the weights as a percentage of each animal’s 
initial weight prior to disease induction, it was clear that the L. lactis - CFA/I mice 
maintained their weight and even continued to grow naturally, whereas weight loss 
occured for both the control group and the L. lactis empty group at the conclusion of the 
experiment.  This suggests that the probiotic alone is insufficient; the expression of the 
irrelevant antigen helps promote oral tolerance that confers protection from the disease. 
 Lastly, it is important to note that the severity of disease in the mice receiving the 
L. lactis empty increased at the end of the experiment.  EAE in C57 mice is extremely 
acute and the mice exhibit quick and strong symptoms of EAE.  While the animals were 
receiving weekly treatments, the L. lactis empty recipients maintained lower clinical 
scores than the control group.  This phenomenon, however, ended when treatments 
ceased and therefore there was no lasting effect of the treatment.  This was not observed 
in the group receiving L. lactis - CFA/I.  Even when the weekly administrations ended, 
the L. lactis - CFA/I recipients maintained lower clinical scores than the control group 
and maintained a healthy weight gain expected of healthy mice.  Although the data is 
preliminary, we speculate that there is enhanced long term protection conferred by the 
probiotic expressing the antigen as opposed to the probiotic alone. 
 Because we did not evaluate the immune cell populations in the animals, we 
cannot conclude that the mechanism of action of L. lactis – CFA/I is equivalent in the 
context of EAE disease.  However, we can, at the least preliminarily, say that the usage of 
L. lactis expressing an irrelevant antigen can induce oral tolerance in the C57 mouse 
model of EAE. Other experiments suggest that the protection brought on by L. lactis - 
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CFA/I is in part due to the activation and maturation of Treg populations, which are 
important.  Further experimentation is needed to expand upon our initial findings.   
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Figures and Tables 
 
Figure 4.1. EAE was induced in 30 mice (n = 10/group) treated with sham, 5 x 108 CFU of L. 
lactis vector, or L. lactis-CFA/I on day 0, 3, and7 post-EAE induction. A) Daily clinical scores. 
Two-way ANOVA followed by multiple comparisons test: Untreated. Vs. L.lacts: φ, p < 0.05; φp 
< 0.01; Untrireated Vs. L. lactis-CFA/I: *, p < 0.05, **, p < 0.01, ***, p < 0.001; L. lactis vs. L. 
lactis-CFA/I: t, p < 0.05. B) Distribution of EAE scores. C) Severity Index, analyzed by one-way 
ANOVA followed by multiple comparisons test.  
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Chapter 5: Digesting the Bi-directionality Between the Gut Microbiome and 
Autoimmunity via Directional Analysis of the Relationship and Interconnectedness 
Evaluated using a Therapeutic Probiotic 
 The importance of the gut microbiome in human health continues to garner 
interest.  We realize, however, that the relationship between the gut microbiome and host 
health is complex.  This complexity associates with many factors including the intestinal 
bacterial populations as well as the resulting health of the individual.  There is overlap 
between these factors; for example, exercising is generally beneficial to human health, 
but studies show that exercise also is beneficial to shaping a health gut microbiome.1  In 
the latter study, rats were subjected to no exercise following a bone fracture and surgery 
for repair.  After a period of time, the rats were then able to exercise which resulted in 
mitigating metabolic distress as well as normalization of the gut microbiome to a healthy 
state.  But what comes first: the metabolic recovery or the gut microbiome recovery?  
They likely are not mutually exclusive events but rather simultaneous and synergistic 
effects.  This paradigm is just one example of the complicated bi-directionality between 
the gut microbiome and host health. 
In the case of autoimmunity, a similar paradigm occurs.  Factors that shape the 
development of autoimmune disorders also influences the gut microbial composition.  
Genetics, diet, lifestyle, geographic location, and disease history all shape the gut 
microbiome as well as predispose individuals to autoimmunity.  The vast overlap 
between risk factors for autoimmunity as well as factors that shape the composition of the 
gut microbiome makes discerning the role each plays in health challenging.  This 
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observation represents the platform of the current thesis, which is to highlight just how 
difficult it is to separate intestinal dysbiosis from autoimmunity. 
Our first goal was to analyze the role autoimmunity has on shaping the gut 
microbiome.  To achieve this, we examined how EAE shaped the composition of gut 
microbiota based on the time point during disease, as well as disease severity.  Using 10-
week old female NOD mice, we induced EAE; using stool collected just before EAE 
induction as a baseline, we analyzed the similarity in microbial composition at various 
times post EAE challenge as well as symptom severity.  As expected, and in light of the 
interconnected relationship of autoimmunity with the gut microbiome, we saw that 
disease itself played a key role in shaping the structure of the gut microbiome.  When 
compared to the control mice in which EAE was not induced, severely ill EAE mice had 
a vastly different gut microbiome composition.  This phenomenon was also observed 
when comparing the mildly ill EAE mice to the control healthy mice; however, the extent 
in dissimilarity between the gut microbiome compositions was less dramatic than that 
seen when comparing severely ill EAE mice and healthy mice.  What this means is that 
the extent of disease plays a role in shaping the overall composition of the gut 
microbiome. 
To demonstrate the other side of the bi-directionality between the gut microbiome 
and autoimmunity, we sought to demonstrate that the gut microbiome plays a role in 
shaping disease severity in EAE.  Again, taking 10-week old NOD mice, we induced 
EAE.  Then, at various time points in the disease, we subjected the mice to broad-
spectrum antibiotics.  The theory behind the use of antibiotics was to eliminate the vast 
majority of the bacterial population in the gut in order to have an unbiased measure of the 
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extent in which the gut microbiome shapes disease.  When the mice were subjected to 
antibiotics during day 0 to day 14 post EAE induction the mice exhibited significantly 
reduced symptoms of EAE.  This suggests that the presence of the gut microbiome 
modulates the severity of disease.  The gut microbiome has been recognized as playing a 
key role in educating host immune systems.  In the case of autism spectrum disorder, 
children with dysbiotic guts have an unbalanced immune system.2  Taking this further, 
new physiological pathways are being identified showing that the host’s immune system 
communicates with the gut microbiome regularly and routinely.3  Therefore, by wiping 
out the presence of the bacteria in the intestines, one can modulate the disease severity.  
That is exactly what we saw during the first phase of EAE in the NOD mice.  
Interestingly enough, we observed the similar effects when antibiotics were used at later 
periods of EAE.  This is explained by the observation that the first phase of EAE is 
highly inflammatory whereas the second phase is more neurodegenerative.  
We further sought to examine the cellular mechanism by which the antibiotics 
reduced EAE severity.  Using previous work, we predicted there would be an effect on 
Treg populations when the gut microbiome was eradicated.  We therefore performed flow 
cytometric analyses on the immune tissue from the gut associated lymphoid tissue.  Here, 
we found that when mice were treated with broad-spectrum antibiotics there was an 
increase in Foxp3+CD39+ populations as well as Foxp3+CD39- cell populations.  This 
was expected based on previous literature, and the fact that we also noted genus level 
deviations between the EAE induced mice that was dependent on disease severity. 
The genus Lactobacillus has been appreciated for its immunomodulatory 
properties,4  and accordingly has been used for probiotic therapies.5  We noted that there 
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was a reduction on Lactobacillus as well as an unspecified genus of the family 
Christensenellaceae between severely ill EAE mice and healthy controls.  While these 
taxa were reduced between those mice, we noted that there was an increase in 
Akkermansia.  Interestingly, Akkermansia has been attributed to being a key player in 
MS.6  Therefore it was not surprising that we saw an increase in the relative abundance of 
Akkermansia in the severely ill EAE mice.  Further, it follows that when we eradicated 
the gut microbiota, a reduction in EAE severity, as well as an increase in Treg 
populations, was observed.  This suggests that an aberrant immunological response (as 
seen in cases of autoimmunity) associate with an aberrant gut microbiome.  Our data 
clearly demonstrated that the gut microbiome plays a role in autoimmunity.  
 Since the gut microbiome is an excellent target for probiotic intervention, we next 
sought to use a genetically modified Lactococcus lactis expressing the CFA/I antigen as a 
therapy for EAE.  It was clear that probiotic intervention had a beneficial impact on 
reducing disease severity of EAE.  Ours represents the first to evaluate the efficacy of this 
genetically modified probiotic in EAE.  The results of the experiment have obvious 
pharmacotherapeutic ramifications, but most importantly, it was clear that targeting the 
gut microbiome had an impact on autoimmunity. 
 This dissertation was targeted to an exploration of the bi-directionality between 
the gut microbiome and autoimmunity.  Supplementing the gut microbiome with a 
probiotic clearly altered the extent of disease.  We speculate that if a 16S rRNA amplicon 
analysis performed on the stool obtained from the animals treated with Lactococcus latics 
would reveal that the overall structure of the gut microbiome would only be minimally 
altered since symptoms of the disease were modulated.  Therefore, future experiments 
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should simultaneously examine the gut microbiome and autoimmunity by manipulating 
both components simultaneously.  Additionally, these future studies could be expanded to 
other forms of autoimmunity and those with other versions of intestinal dysbiosis.  In the 
case of Lactococcus lactis expressing the CFA/I antigen, we sought to induce oral 
tolerance with an irrelevant antigen.  We speculate that the modulation of oral tolerance 
associates with GABA increases which confer protection against EAE.  We believe that 
manipulation of the gut microbiome has broad relevance to human health with expansive 
new pharmaceutical potential. 
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RESEARCH 
EXPERIENCE                                                                                                                      
Research Tech. II,  Washington State University                                          2018 
Laboratory of Dr. Gibson.  
 
Graduate Student Researcher, Eastern Washington University        2016-2018 
Studied the gut microbiome of non-obese diabetic mice induced 
with experimental autoimmune encephalomyelitis.  Compared the 
gut microbiome between the Multiple Sclerosis model and the 
Diabetic model in both structure and function.  Collected fecal 
pellets for 16 S rRNA analysis, obtained gut associated lymphoid 
tissue for immune cell phenotyping, performed western blots on 
the intestinal epithelium to assess intestinal permeability, assessed 
clinical scores for the mouse model, performed statistical analysis 
and helped with the animal housing and care.  Laboratory of Dr. 
Ochoa-Repáraz. 
 
Undergraduate Student Researcher, Eastern Washington University       2015-2016 
Studied the gut microbiome of non-obese diabetic mice induced 
with experimental autoimmune encephalomyelitis.  Collected fecal 
pellets for 16S rDNA analysis, obtained gut associated lymphoid 
tissue for immune cell phenotyping, assessed clinical scores for the 
mouse model, and helped with the animal housing and care.  
Laboratory of Dr. Ochoa-Repáraz. 
 
Undergraduate Student Researcher, Elmhurst College                    2013-2014 
Performed RNA extractions and dissections on brain tissue 
obtained from Drosophila melanogaster.  The overall goal of the 
experiment was to observe the impacts of ethanol rearing on the 
JAK-STAT pathway. Laboratory of Dr. McClure 
 
Assistant Laboratory Technician, Loyola University         2013 
Helped doctoral students as well as post-docs by creating media for 
cloning genetically modified E. coli with the human TRIM-5α 
gene.  Performed protein purification and extraction of the TRIM-
5α protein. Laboratory of Dr. Campbell. 
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TEACHING 
EXPERIENCE                                                                                                                      
Hematology Graduate Teaching Assistant                                2018 
Eastern Washington University 
Lecture and laboratory practice addressing the basics of 
Hematology. Taught students about erythrocytes, leukocytes, 
hematocrits, blood typing, identifying types of anemia and 
leukemia from blood smears, and how to prepare blood smears. 
 
Microbiology Graduate Teaching Assistant                      2016-2018 
Eastern Washington University 
Lecture and laboratory practice addressing the basics of 
microbiology. Taught students basic and differential staining 
procedures, bacterial plating and culture, bacterial streaking, 
aseptic technique, and common techniques of microbiology. 
 
Departmental Microbiome Capstone Graduate Teaching Assistant             2017-2018 
Eastern Washington University 
Led students in study of current literature and development of 
individual research projects concerning the gut microbiome in 
murine models.  
 
Elementary Medical Microbiology Graduate Teaching Assistant        2016-2017 
Eastern Washington University 
Lecture and general microbiology laboratory practice. Taught 
students basic and differential staining procedures, bacterial plating 
and culture, bacterial streaking, aseptic technique, and common 
techniques used in hospital laboratory settings. 
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COMMUNITY OUTREACH                                                            _______                   
Inland Northwest Concerned Scientists                            2017-2018 
Member; non-partisan organization that brings together scientists, 
professionals and concerned citizens to encourage the appreciation 
of science, science-based policy making, and to support current 
and future scientists in upholding these values, with special 
emphasis on local and regional issues.  
 
Washington State Science Olympiad - Microbe Mission                               2017-2018 
Helped design, proctored, and graded exams for both middle 
school and high school students. 
ADDITIONAL EXPERIENCE                                                                                           
Graduate Student Liaison                       2017-2018  
Attended faculty meetings and provided a line of communication 
between faculty and graduate students.  Informed both populations 
of current events.  Helped program lunch-ins for graduate students 
and prospective faculty members as well as provided campus tours 
for prospective faculty members.  Coordinated social events for 
faculty and students to enrich the educational process. 
 
Roving Naturalist                        2012-2013 
Roving Naturalist for the Brookfield Zoo under the Conservation, 
Education, and Training department 
Performed inquiry based projects with the general public as well as 
my department.  Most inquiries related to Pteropus rodricensus 
and Desmodus rotundus.  The inquiries were designed to explore 
the social behavior between bat types and to investigate if human 
disturbances altered social behavior.  Also worked with the locals 
to establish native species based gardens to benefit migrating 
Danaus plexippus populations.  Educated general public at the 
Coast, the Garden, the Australasia House, and the Sting-ray Bay 
exhibits. 
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TECHNICAL EXPERTISE                                                                                                 
Fluent in gut microbiome analysis and interpretation by 16S rDNA analysis and 
PICRUSt; Nephele through the NIH; Dissection and collection of immunological tissue; 
Immune cell phenotyping via flow cytometry; Sample analysis via SDS-PAGE 
electrophoresis and Western blotting; Bacterial culturing and analysis; buffer preparation; 
IACUC procedures; Murine husbandry; Murine exsanguination. 
Experienced with writing IACUC protocols; Statistical analysis with R; DNA/RNA 
extractions; Administration of oral gavage; Prepping tissues for immunohistology assays; 
Protein extractions and purification from bacterial samples. 
 
